WO2021127214A1 - Synthetic processes and intermediates - Google Patents

Synthetic processes and intermediates Download PDF

Info

Publication number
WO2021127214A1
WO2021127214A1 PCT/US2020/065666 US2020065666W WO2021127214A1 WO 2021127214 A1 WO2021127214 A1 WO 2021127214A1 US 2020065666 W US2020065666 W US 2020065666W WO 2021127214 A1 WO2021127214 A1 WO 2021127214A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
salt
preparing
converting
Prior art date
Application number
PCT/US2020/065666
Other languages
French (fr)
Other versions
WO2021127214A4 (en
Inventor
Mahesh PALLERLA
Ganapati Reddy Pamulapati
Jan SPINK
Original Assignee
Arbutus Biopharma Corporation
Arbutus Biopharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arbutus Biopharma Corporation, Arbutus Biopharma, Inc. filed Critical Arbutus Biopharma Corporation
Priority to EP20903872.8A priority Critical patent/EP4077473A4/en
Priority to CA3165101A priority patent/CA3165101A1/en
Priority to IL294064A priority patent/IL294064A/en
Priority to JP2022537683A priority patent/JP2023510109A/en
Priority to AU2020408039A priority patent/AU2020408039A1/en
Priority to US17/787,089 priority patent/US20230113948A1/en
Priority to BR112022012226A priority patent/BR112022012226A2/en
Priority to KR1020227022805A priority patent/KR20220119052A/en
Priority to CN202080089979.8A priority patent/CN114846051A/en
Priority to MX2022007738A priority patent/MX2022007738A/en
Publication of WO2021127214A1 publication Critical patent/WO2021127214A1/en
Publication of WO2021127214A4 publication Critical patent/WO2021127214A4/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
    • C07C201/06—Preparation of nitro compounds
    • C07C201/12—Preparation of nitro compounds by reactions not involving the formation of nitro groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/39—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by esterified hydroxy groups
    • C07C205/42—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by esterified hydroxy groups having nitro groups or esterified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/02—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/08—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/34—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having amino groups and esterified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/04—Formation of amino groups in compounds containing carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/10—Preparation of carboxylic acid amides from compounds not provided for in groups C07C231/02 - C07C231/08
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/74—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/16—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/02—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from isocyanates with formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/04—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from amines with formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/08—Polyoxyalkylene derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Definitions

  • HBV Hepatitis B virus
  • Hepatitis D virus is a small circular enveloped RNA virus that can propagate only in the presence of the hepatitis B virus (HBV).
  • HBV hepatitis B virus
  • HDV requires the HBV surface antigen protein to propagate itself. Infection with both HBV and HDV results in more severe complications compared to infection with HBV alone.
  • hepatitis D In combination with hepatitis B virus, hepatitis D has the highest mortality rate of all the hepatitis infections.
  • International Patent Application Publication Number WO 2018/191278 describes conjugates that are useful to target siRNA to the liver that are suitable for treating, e.g., HBV and/or HDV. Currently there is a need for synthetic processes and synthetic intermediates that can be used to prepare such conjugates.
  • the invention provides synthetic processes and synthetic intermediate compounds that can be used to prepare therapeutic conjugates.
  • the invention also provides a method for treating HBV and/or HDV infection in a human by administering a therapeutic conjugate prepared by a method of the invention.
  • the invention also provides a method for treating HBV and/or HDV infection in a human subject comprising administering to the human subject, a therapeutically effective amount of a therapeutic conjugate prepared by a methods of the invention, and a second therapeutic agent that is useful for treating HBV and/or HDV.
  • the invention also provides a compound prepared by a method of the invention.
  • the invention also provides a therapeutic conjugate prepared by a method of the invention for use in medical therapy.
  • the invention also provides a therapeutic conjugate prepared by a method of the invention for the prophylactic or therapeutic treatment of HBV and/or HDV, optionally in combination with another therapeutic agent.
  • the invention also provides the use of a therapeutic conjugate prepared by a method of the invention to prepare a medicament for the treatment of HBV and/or HDV, optionally in combination with another therapeutic agent.
  • alkyl by itself or as part of another substituent, means, unless otherwise stated, a straight or branched chain hydrocarbon radical, having the number of carbon atoms designated (i.e., C 1-8 means one to eight carbons).
  • Examples include (C 1 -C 8 )alkyl, (C 2 -C 8 )alkyl,C 1 -C6)alkyl, (C 2 -C6)alkyl and (C 3 -C6)alkyl.
  • alkyl groups include methyl, ethyl, n- propyl, iso-propyl, n-butyl, t-butyl, iso-butyl, sec-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, and and higher homologs and isomers.
  • protecting group refers to a substituent that is commonly employed to block or protect a particular functional group on a compound.
  • an “amino-protecting group” is a substituent attached to an amino group that blocks or protects the amino functionality in the compound.
  • Suitable amino-protecting groups include acetyl, trifluoroacetyl, t-butoxycarbonyl (BOC), benzyloxycarbonyl (CBZ) and 9- fluorenylmethylenoxycarbonyl (Fmoc).
  • a "hydroxy-protecting group” refers to a substituent of a hydroxy group that blocks or protects the hydroxy functionality. Suitable protecting groups include acetyl and silyl.
  • a “carboxy-protecting group” refers to a substituent of the carboxy group that blocks or protects the carboxy functionality.
  • Common carboxy- protecting groups include phenylsulfonylethyl, cyanoethyl, 2-(trimethylsilyl)ethyl, 2- (trimethylsilyl)ethoxymethyl, 2-(p-toluenesulfonyl)ethyl, 2-(p-nitrophenylsulfenyl)ethyl, 2- (diphenylphosphino)-ethyl, nitroethyl and the like.
  • protecting groups and their use see P.G.M. Wuts and T.W.
  • a wavy line “ ” that intersects a bond in a chemical structure indicates the point of attachment of the bond that the wavy bond intersects in the chemical structure to the remainder of a molecule.
  • a bond in a compound formula herein is drawn in a non-stereochemical manner (e.g. flat), the atom to which the bond is attached includes all stereochemical possibilities.
  • a bond in a compound formula herein is drawn in a defined stereochemical manner (e.g.
  • the compound may be at least 51% the absolute stereoisomer depicted. In another embodiment, the compound may be at least 60% the absolute stereoisomer depicted. In another embodiment, the compound may be at least 80% the absolute stereoisomer depicted. In another embodiment, the compound may be at least 90% the absolute stereoisomer depicted. In another embodiment, the compound may be at least 95 the absolute stereoisomer depicted. In another embodiment, the compound may be at least 99% the absolute stereoisomer depicted.
  • capsid inhibitor includes compounds that are capable of inhibiting the expression and/or function of a capsid protein either directly or indirectly.
  • a capsid inhibitor may include, but is not limited to, any compound that inhibits capsid assembly, induces formation of non-capsid polymers, promotes excess capsid assembly or misdirected capsid assembly, affects capsid stabilization, and/or inhibits encapsidation of RNA.
  • Capsid inhibitors also include any compound that inhibits capsid function in a downstream event(s) within the replication process (e.g., viral DNA synthesis, transport of relaxed circular DNA (rcDNA) into the nucleus, covalently closed circular DNA (cccDNA) formation, virus maturation, budding and/or release, and the like).
  • the inhibitor detectably inhibits the expression level or biological activity of the capsid protein as measured, e.g., using an assay described herein.
  • the inhibitor inhibits the level of rcDNA and downstream products of viral life cycle by at least 5%, at least 10%, at least 20%, at least 50%, at least 75%, or at least 90%.
  • capsid inhibitor includes compounds described in International Patent Applications Publication Numbers WO2013006394, WO2014106019, and WO2014089296, including the following compounds: .
  • the term capsid inhibitor also includes the compounds Bay-41-4109 (see International Patent Application Publication Number WO/2013/144129), AT-61 (see International Patent Application Publication Number WO/1998/33501; and King, RW, et al., Antimicrob Agents Chemother., 1998, 42, 12, 3179–3186), DVR-01 and DVR-23 (see International Patent Application Publication Number WO 2013/006394; and Campagna, MR, et al., J.
  • sAg Secretion Inhibitors/RNA Destabilizers As described herein the term “sAg secretion inhibitor” includes compounds that are capable of inhibiting, either directly or indir tl th etion of sAg (S, M and/or L surface antigens) bearing subviral particles and/or DNA containing viral particles from HBV-infected cells. As used herein, “sAg secretion inhibitors” are also known as “RNA destabilizers”, and these terms are used interchangeably.
  • the inhibitor detectably inhibits the secretion of sAg as measured, e.g., using assays known in the art or described herein, e.g., ELISA assay or by Western Blot.
  • the inhibitor inhibits the secretion of sAg by at least 5%, at least 10%, at least 20%, at least 50%, at least 75%, or at least 90%.
  • the inhibitor reduces serum levels of sAg in a patient by at least 5%, at least 10%, at least 20%, at least 50%, at least 75%, or at least 90%.
  • sAg secretion inhibitor includes compounds described in United States Patent Number 8,921,381, as well as compounds described in United States Patent Application Publication Numbers 2015/0087659 and 2013/0303552.
  • the term includes the compounds PBHBV-001 and PBHBV-2-15, and pharmaceutically acceptable salts thereof: . Specific embodiments of the invention are described below.
  • the invention provides a method for preparing a compound of formula 1: comprising reacting a compound of formula 1-1: with a compound of formula 1-2: at a temperature of 40 °C or greater to provide the compound of formula 1.
  • the reaction can be carried out neat or in the presence of one or more solvents.
  • the invention is carried out in a polar aprotic solvent, such as, for example, tetrahydrofuran, 1,2-dichloroethene, methyltetrahydrofuran, toluene, acetonitrile, dimethoxyethane, or carbon tetrachloride.
  • a polar aprotic solvent such as, for example, tetrahydrofuran, 1,2-dichloroethene, methyltetrahydrofuran, toluene, acetonitrile, dimethoxyethane, or carbon tetrachloride.
  • the reaction is carried out at a temperature in the range from about 0 °C to about 100 °C.
  • the reaction is carried out at a temperature of 60 °C or greater.
  • the reaction is carried out at a temperature in the range from about 60 °C to about 80 °C.
  • the invention provides a method for preparing a crystalline form of compound 3: comprising converting a compound of formula 1: to the crystalline form of compound 3 without using column chromatography during the conversion.
  • the compound can be crystallized from a solvent that comprises dichloromethane or ethyl acetate.
  • the compound is crystallized from dichloromethane or ethyl acetate.
  • the invention provides a crystalline form of compound 3: .
  • the invention provides a method for preparing a compound of formula 9: wherein R 9 is an optionally substituted benzyloxycarbonyl group, comprising converting a compound of formula 8: or a salt thereof to the compound of formula 9.
  • the conversion can be carried out at any suitable temperature and can be carried out neat or in the presence of one or more solvents.
  • the conversion is carried out in a polar or nonpolar aprotic solvent, such as, for example, dichloromethane, chloroform, tetrahydrofuran, methyltetrahydrofuran, carbon tetrachloride, acetonitrile, pyridine, dimethylformamide, dimethylacetamide, or toluene.
  • the conversion is carried out at a temperature in the range from about 0 °C to about 100 °C.
  • the conversion is carried out at a temperature in the range from about 15 °C to about 25 °C.
  • R 9 is benzyloxycarbonyl or nitrobenzyloxycarbonyl.
  • the compound of formula 8 is converted to the compound of formula 9 by treating the compound of formula 8 with benzyloxycarbonyl chloride in a suitable solvent in the presence of a suitable base.
  • the base is an amine base, such as, for example, trimethylamine, triethylamine, pyridine, dimethylaminopyridine, diisopropylethylamine, or tripropyl amine.
  • the invention provides a method for preparing a compound of formula 10: wherein R 9 is an optionally substituted benzyloxycarbonyl group, comprising converting a corresponding compound of formula 9: to the compound of formula 10.
  • the conversion can be carried out at any suitable temperature and can be carried out neat or in the presence of one or more solvents.
  • the conversion provides the compound of formula 10 as at least about 85%, 90%, or 95% the beta- isomer.
  • the conversion is carried out in a nonpolar aprotic solvent, such as, for example, dichloroethane, dichloromethane, acetonitrile, methyltetrahydro- furan, tetrahydrofuran, dimethoxyethane, or toluene.
  • a nonpolar aprotic solvent such as, for example, dichloroethane, dichloromethane, acetonitrile, methyltetrahydro- furan, tetrahydrofuran, dimethoxyethane, or toluene.
  • the conversion is carried out at a temperature in the range from about 0 °C to about 100 °C.
  • the conversion is carried out at a temperature in the range from about 80 °C to about 85 °C.
  • the conversion is carried out at a temperature in the range from about 35 °C to about 45 °C.
  • the conversion is carried out at a temperature in the range from about 45 °C to about 55 °C. In another embodiment, the conversion is carried out at a temperature in the range from about 55 °C to about 65 °C. In another embodiment, the conversion is carried out at a temperature that optimizes the beta:alpha ratio of the product.
  • R 9 is benzyloxycarbonyl or nitrobenzyloxycarbonyl. In one embodiment, the compound of formula 9 is converted to the compound of formula 10 by treatment with a compound of formula 7: in the presence of a suitable catalyst and a suitable solvent.
  • the catalyst is Sc(OTf)3, trimethylsilyl trifluoromethanesulfonate, zinc chloride, or 4A molecular sieves.
  • the invention provides a method for preparing a compound of formula 10: wherein R 9 is an optionally substituted benzyloxycarbonyl group, comprising converting a compound of formula 8: or a salt thereof to a corresponding compound of formula 9; and subsequently converting the corresponding compound of formula 9 to the compound of formula 10, without purifying the compound of formula 9 by chromatography.
  • the invention provides a method for preparing a salt of formula 11: comprising treating a compound of formula 10: wherein R 9 is an optionally substituted benzyloxycarbonyl group, with hydrogen and trifluoroacetic acid in the presence of a suitable catalyst and in the presence of a suitable solvent.
  • the suitable catalyst comprises palladium on carbon.
  • the suitable solvent comprises tetrahydrofuran.
  • the reaction can be carried out at any suitable temperature. In one embodiment, the reaction is carried out at a temperature in the range from about 0 °C to about 50 °C. In another embodiment, the reaction is carried out at a temperature in the range from about 20 °C to about 25 °C.
  • R 9 is benzyloxycarbonyl or nitrobenzyloxycarbonyl.
  • the invention provides a method for preparing a compound of formula 15D: or a salt thereof, comprising converting a compound of formula 15C: wherein each R 15 is a (C 1 -C 6 )alkyl, to the compound of formula 15D or the salt thereof.
  • the conversion can be carried out at any suitable temperature and can be carried out neat or in the presence of one or more solvents.
  • the conversion is carried out in a polar protic solvent, such as, for example, methanol, ethanol, tetrahydrofuran, and/or water.
  • the conversion is carried out at a temperature in the range from about 0 °C to about 100 °C. In another embodiment, the conversion is carried out at a temperature in the range from about 15 °C to about 25 °C. In one embodiment, the conversion is carried out in the presence of a suitable base, such as, for example, sodium hydroxide, lithium hydroxide, or potassium hydroxide.
  • a suitable base such as, for example, sodium hydroxide, lithium hydroxide, or potassium hydroxide.
  • the invention provides a method for preparing a compound of formula 15C: wherein each R 15 is a (C 1 -C 6 )alkyl, comprising reacting a compound of formula 15A: or a salt thereof, with a corresponding compound of formula 15B: or a salt thereof, to provide the compound of formula 15C.
  • the reaction can be carried out at any suitable temperature and can be carried out neat or in the presence of one or more solvents.
  • the reaction is carried out in a polar aprotic solvent, such as, for example, dimethylformamide, dichloromethane, 1,2-dichloroethane, or dimethylacetamide.
  • the reaction is carried out at a temperature in the range from about 0 °C to about 50 °C.
  • the reaction is carried out at a temperature in the range from about5 °C to about 10 °C.
  • the reaction is carried out in the presence of a suitable base.
  • the base is a hindered amine base, such as, for example, diisopropylethylamine, trimethylamine, pyridine, or dimethylaminopyridine.
  • the reaction is carried out in the presence of a suitable coupling agent, such as, for example, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide EDC, N,N′-dicyclohexyl- carbodiimide DCC, (1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3- oxide hexafluorophosphate HATU, (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate HBTU, or propanephosphonic acid anhydride T3P).
  • a suitable coupling agent such as, for example, 1-ethyl-3-(3-dimethylaminoprop
  • the invention provides a method for preparing a compound of formula 13A: wherein each R 15 is a (C 1 -C 6 )alkyl, comprising converting a corresponding compound of formula 15C: wherein each R 15 is a (C 1 -C 6 )alkyl, to the compound of formula 13A.
  • the conversion can be carried out at any suitable temperature and can be carried out neat or in the presence of one or more solvents.
  • the conversion is carried out in a polar protic solvent, such as, for example, methanol, ethyl acetate, tetrahydrofuran, methyltetrahydrofuran, or ethanol.
  • the conversion is carried out at a temperature in the range from about 0 °C to about 100 °C. In another embodiment, the conversion is carried out at a temperature in the range from about 15 °C to about 25 °C. In one embodiment, the conversion is carried out in the presence of a suitable catalyst, such as, for example, palladium on carbon or Pd(OH)2.
  • a suitable catalyst such as, for example, palladium on carbon or Pd(OH)2.
  • the invention provides a method for preparing a compound of formula 13B: wherein each R 15 is a (C 1 -C 6 )alkyl and T is an optionally substituted triphenylmethyl group, comprising converting a corresponding com d f f mula 13A: to the compound of formula 13B.
  • the conversion can be carried out at any suitable temperature and can be carried out neat or in the presence of one or more solvents.
  • the conversion is carried out in a nonpolar aprotic solvent, such as, for example, dichloromethane, 1,2-dichloroethane, dimethylformamide, or dimethylacetamide.
  • the conversion is carried out at a temperature in the range from about -78 °C to about 100 °C.
  • the conversion is carried out at a temperature in the range from about 0 °C to about 30 °C.
  • the conversion is carried out in the presence of a suitable coupling agent, such as, for example, 1-ethyl-3-(3-dimethylamino- propyl)carbodiimide EDC, N,N′-dicyclohexylcarbodiimide DCC, (1-[bis(dimethylamino)- methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate HATU, (2-(1H- benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate HBTU, or propanephosphonic acid anhydride T3P).
  • a suitable coupling agent such as, for example, 1-ethyl-3-(3-dimethylamino- propyl)carbodiimide EDC, N,N′-dicyclohexylcarbodiimide DCC, (1-[bis(dimethylamino)-
  • the compound of formula 13A is converted to the compound of formula 13B, by treating the compound of formula 13A with a corresponding compound of formula 6: or a salt thereof, wherein DMTr is 4,4-dimethoxytriphenylmethyl under suitable amide forming conditions.
  • the compound of formula 13A is treated with the compound of formula: in dichloromethane at a temperature in the range from about 0 °C to about 30 °C in the presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide.
  • the invention provides a method for preparing a compound of formula 13C: comprising converting a compound of formula 13B: wherein each R 15 is a (C 1 -C 6 )alkyl and T is an optionally substituted triphenylmethyl group, to the compound of formula 13C.
  • the conversion can be carried out at any suitable temperature and can be carried out neat or in the presence of one or more solvents.
  • the conversion is carried out in a polar protic solvent, such as, for example, methanol, ethanol, tetrahydrofuran, and/or water.
  • the conversion is carried out at a temperature in the range from about 0 °C to about 100 °C.
  • the conversion is carried out at a temperature in the range from about 20 °C to about 40 °C. In one embodiment, the conversion is carried out in the presence of a suitable base, such as, for example, potassium hydroxide, lithium hydroxide, or sodium hydroxide.
  • a suitable base such as, for example, potassium hydroxide, lithium hydroxide, or sodium hydroxide.
  • the compound of formula 13B is converted to the compound of formula 13C by treatment with potassium hydroxide in a solvent comprising methanol and water.
  • the invention provides a method for preparing a crystalline potassium salt of a compound of formula 13CC: comprising treating a compound of formula 13CC or a salt thereof with potassium hydroxide in methanol.
  • the crystalline potassium salt of a compound of formula 13CC can be prepared as described in Example 30.
  • the invention provides a method for preparing a compound of formula 11B: comprising converting a compound of formula 11A: or a salt thereof, to the compound of formula 11B.
  • the conversion can be carried out at any suitable temperature and can be carried out neat or in the presence of one or more solvents.
  • the conversion is carried out in a nonpolar aprotic solvent, such as, for example, dichloromethane, 1,2-dichloroethane, methyltetrahydrofuran, tetrahydrofuran, dimethylformamide, or dimethylacetamide.
  • the conversion is carried out at a temperature in the range from about 0 °C to about 100 °C.
  • the conversion is carried out at a temperature in the range from about 5 °C to about 30 °C.
  • the compound of formula 11A is converted to the compound of formula 11B by treating the compound of formula 11A or the salt thereof with 1-ethyl-3-(3- dimethylaminopropyl)carbodiimide EDC, N,N′-dicyclohexylcarbodiimide DCC, (1- [bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate HATU, (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate HBTU, or propanephosphonic acid anhydride T3P) in dichloromethane.
  • the invention provides a method for preparing a compound of formula 12:
  • the conversion can be carried out at any suitable temperature and can be carried out neat or in the presence of one or more solvents.
  • the conversion is carried out in a nonpolar aprotic solvent, such as, for example, dichloromethane, 1,2-dichloroethane, methyltetrahydrofuran, tetrahydrofuran, dimethylformamide, or dimethylacetamide.
  • the conversion is carried out at a temperature in the range from about 0 °C to about 50 °C. In another embodiment, the conversion is carried out at a temperature in the range from about 0 °C to about 30 °C.
  • the conversion is carried out in the presence of a suitable base.
  • the base is a hindered amine base, such as, for example, diisopropylethylamine, trimethylamine, dimethylaminopyridine, or pyridine.
  • the compound of formula 11B is converted to the compound of formula 12 by treating the compound of formula 11B with a compound of formula 11: or a salt thereof, in the presence of a suitable base and a suitable solvent.
  • the compound of formula 11B is converted to the compound of formula 12 by treating the compound of formula 11B with the trifloroacetic acid salt of a compound of formula 11: in the presence of diisopropylethylamine and a solvent that comprises dichloromethane.
  • the invention provides a method for preparing a compound of formula 13: or a salt thereof, comprising reducing a compound of formula 12: to provide the compound of formula 13 or the salt thereof.
  • the reduction can be carried out at any suitable temperature and can be carried out neat or in the presence of one or more solvents.
  • the reduction is carried out in a polar aprotic solvent, such as, for example, tetrahydrofuran, methyltetrahydrofuran, or ethyl acetate.
  • the reduction is carried out at a temperature in the range from about 0 °C to about 50 °C.
  • the reduction is carried out at a temperature in the range from about 0 °C to about 30 °C. In one embodiment, the reduction is carried out in the presence of a suitable catalyst, such as, for example, palladium on carbon.
  • a suitable catalyst such as, for example, palladium on carbon.
  • the compound of formula 13 or the salt thereof is a trifluoroacetic acid salt of the following formula: .
  • the invention provides a method for preparing a compound of formula 14: comprising converting a compound of formula 13: or a salt thereof to the compound of formula 14. The conversion can be carried out at any suitable temperature and can be carried out neat or in the presence of one or more solvents.
  • the conversion is carried out in a nonpolar aprotic solvent, such as, for example, dichloromethane, 1,2-dichloroethane, methyltetrahydrofuran, tetrahydrofuran, dimethylformamide, or dimethylacetamide.
  • a nonpolar aprotic solvent such as, for example, dichloromethane, 1,2-dichloroethane, methyltetrahydrofuran, tetrahydrofuran, dimethylformamide, or dimethylacetamide.
  • the conversion is carried out at a temperature in the range from about -78 °C to about 25 °C.
  • the conversion is carried out at a temperature in the range from about -25 °C to about 30 °C.
  • the conversion is carried out in the presence of a suitable base.
  • the base is an amine base, such as, for example, trimethylamine, triethylamine, diisopropylethylamine, dimethylaminopyridine, pyridine, or tripropylamine.
  • the conversion is carried out in the presence of a suitable coupling reagent, such as, for example, propanephosphonic acid anhydride.
  • the compound of formula 13 is converted to the compound of formula 14, by treating the compound of formula 13 with a compound of formula: or a salt thereof, in a solvent comprising dichloromethane in the presence of a coupling agent, such as, for example, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide EDC, (1- [bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate HATU, (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate HBTU, or propanephosphonic acid anhydride T3P, at a temperature n the range from about -15 °C to about 15 °C.
  • a coupling agent such as, for example, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide E
  • the invention provides a method for preparing a compound of formula 16: wherein R 16 is an amine protecting group, comprising converting a compound of formula 13: or a salt thereof, to the compound of formula 16.
  • the conversion can be carried out at any suitable temperature and can be carried out neat or in the presence of one or more solvents.
  • the conversion is carried out in a nonpolar aprotic solvent, such as, for example, dichloromethane, 1,2-dichloroethane, methyltetrahydrofuran, tetrahydrofuran, dimethylformamide, or dimethylacetamide.
  • the conversion is carried out at a temperature in the range from about -78 °C to about 50 °C.
  • the conversion is carried out at a temperature in the range from about -25 °C to about 50 °C. In one embodiment, the conversion is carried out in the presence of a suitable base.
  • the base is an amine base, such as, for example, trimethylamine, triethylamine, or tripropylamine, diisopropylethylamine, dimethylaminopyridine, or pyridine.
  • the conversion is carried out in the presence of a suitable coupling reagent, such as, for example, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide EDC, (1- [bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate HATU, (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate HBTU, or propanephosphonic acid anhydride T3P.
  • a suitable coupling reagent such as, for example, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide EDC, (1- [bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate HATU, (2-
  • the compound of formula 13 or the salt thereof is converted to the compound of formula 16, by treating the compound of formula 13 with a corresponding compound of formula 15DD: wherein R 16 is an amine protecting group, or a salt thereof, under suitable coupling conditions.
  • a trifluoroacetic acid salt of a compound of formula 13: is treated with a compound of formula 15D wherein R 16 is benzyloxycarbonyl: under suitable coupling conditions to provide a compound of formula 16 wherein R 16 is benzyloxycarbonyl.
  • the compound of formula 13 is treated with the compound of formula 15D or 15DD in the presence of propanephosphonic acid anhydride, trimethylamine, and a solvent comprising dichloromethane to provide the compound of formula 16.
  • the invention provides a method for preparing a compound of formula 18: wherein R 18 is a suitable protecting group, comprising converting a compound of formula 13: or a salt thereof, to the compound of formula 18.
  • the conversion can be carried out at any suitable temperature and can be carried out neat or in the presence of one or more solvents.
  • the conversion is carried out in a nonpolar aprotic solvent, such as, for example, dichloromethane, 1,2-dichloroethane, methyltetrahydrofuran, tetrahydrofuran, dimethylformamide, or dimethylacetamide.
  • the conversion is carried out at a temperature in the range from about -78 °C to about 50 °C.
  • the conversion is carried out at a temperature in the range from about -25 °C to about 50 °C. In one embodiment, the conversion is carried out in the presence of a suitable base.
  • the base is an amine base, such as, for example, trimethylamine, triethylamine, or tripropylamine, diisopropylethylamine, dimethylaminopyridine, or pyridine.
  • the conversion is carried out in the presence of a suitable coupling reagent, such as, for example, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide EDC, (1- [bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate HATU, (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate HBTU, or propanephosphonic acid anhydride T3P.
  • a suitable coupling reagent such as, for example, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide EDC, (1- [bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate HATU, (2-
  • the compound of formula 13 or the salt thereof is converted to the compound of formula 18, by treating the compound of formula 13 or the salt thereof with a compound of formula 13CCC: wherein R 18 is a suitable protecting group, or a salt thereof, under suitable coupling conditions.
  • a trifluoroacetic acid salt of a compound of formula 13: is treated with a compound of formula 13CCC, wherein R 18 is 4,4-dimethoxytriphenylmethyl under suitable coupling conditions to provide a compound of formula 18:
  • the compound of formula 13 is treated with the compound of formula 13CCC in the presence of propanephosphonic acid anhydride, trimethylamine, and a solvent comprising dichloromethane to provide the compound of formula 18.
  • the invention provides a method for preparing a compound of formula 16-2: comprising converting a compound of formula 16-1: or a salt thereof, to the compound of formula 16-2. The conversion can be carried out at any suitable temperature and can be carried out neat or in the presence of one or more solvents.
  • the conversion is carried out in a nonpolar aprotic solvent, such as, for example, dichloromethane, 1,2-dichloroethane, chloroform, or carbon tetrachloride.
  • a nonpolar aprotic solvent such as, for example, dichloromethane, 1,2-dichloroethane, chloroform, or carbon tetrachloride.
  • the conversion is carried out at a temperature in the range from about -78 °C to about 100 °C.
  • th ion is carried out at a temperature in the range from about -0 °C to about 30 °C.
  • the conversion is carried out by activating the carboxylic acid groups in the compound of formula 16-1, for example, by treating the compound of formula 16-1 with oxalyl chloride, and treating the resulting carboxylic acid chloride groups with tert-butanol to provide the compound of formula 16-2.
  • the invention provides a method for preparing a compound of formula 16-3: comprising converting a compound of formula 16-2: to the compound of formula 16-3.
  • the conversion can be carried out at any suitable temperature and can be carried out neat or in the presence of one or more solvents.
  • the conversion is carried out in a polar protic solvent, such as, for example, methanol or ethanol.
  • the reaction is carried out at a temperature in the range from about -78 °C to about 50 °C. In another embodiment, the conversion is carried out at a temperature in the range from about -0 °C to about 50 °C. In one embodiment, the conversion is carried out in the presence of a suitable catalyst, such as, for example, palladium on carbon. In one embodiment, the invention provides a method for preparing a compound of formula 16-4: comprising converting a compound of formula 16-3: to the compound of formula 16-4. The conversion can be carried out at any suitable temperature and can be carried out neat or in the presence of one or more solvents.
  • the conversion is carried out in a nonpolar aprotic solvent, such as, for example, dichloromethane, 1,2-dichloroethane, methyltetrahydrofuran, tetrahydrofuran, dimethylformamide, or dimethylacetamide.
  • a nonpolar aprotic solvent such as, for example, dichloromethane, 1,2-dichloroethane, methyltetrahydrofuran, tetrahydrofuran, dimethylformamide, or dimethylacetamide.
  • the conversion is carried out at a temperature in the range from about -78 °C to about 50 °C.
  • the conversion is carried out at a temperature in the range from about -0 °C to about 50 °C.
  • the conversion is carried out in the presence of a suitable base.
  • the base is an amine base, such as, for example, trimethylamine, triethylamine, or tripropylamine, diisopropylethylamine, dimehylaminopyridine, or pyridine.
  • the conversion is carried out in the presence of a suitable coupling reagent, such as, for example, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide EDC, (1-[bis(dimethylamino)methylene]-1H- 1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate HATU, (2-(1H-benzotriazol-1-yl)- 1,1,3,3-tetramethyluronium hexafluorophosphate HBTU, or propanephosphonic acid anhydride T3P.
  • the invention provides a method for preparing a compound of formula 16-5: or a salt thereof, comprising converting
  • the conversion can be carried out at any suitable temperature and can be carried out neat or in the presence of one or more solvents.
  • the conversion is carried out in a polar protic solvent, such as, for example, methanol, ethanol, tetrahydrofuran, or ethyl acetate.
  • the conversion is carried out at a temperature in the range from about -78 °C to about 50 °C.
  • the conversion is carried out at a temperature in the range from about -0 °C to about 50 °C.
  • the conversion is carried out in the presence of a suitable catalyst, such as, for example, palladium on carbon.
  • the invention provides a method for preparing a compound of formula 16D: or a salt thereof, comprising converting a compound of formula 16-5: to the compound of formula 16D.
  • the conversion can be carried out at any suitable temperature and can be carried out neat or in the presence of one or more solvents.
  • the conversion is carried out in a nonpolar aprotic solvent, such as, for example, dichloromethane, 1,2-dichloroethane, methyltetrahydrofuran, tetrahydrofuran, dimethylformamide, or dimethylacetamide.
  • the conversion is carried out at a temperature in the range from about -78 °C to about 50 °C.
  • the conversion is carried out at a temperature in the range from about 0 °C to about 50 °C. In one embodiment, the conversion is carried out in the presence of a suitable base.
  • the base is an amine base, such as, for example, trimethylamine, triethylamine, or tripropylamine, diisopropylethylamine, dimethylaminopyridine, or pyridine.
  • the conversion is carried out in the presence of a suitable coupling reagent, such as, for example, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide EDC, (1-[bis(dimethyl- amino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate HATU, (2- (1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate HBTU, or propanephosphonic acid anhydride T3P.
  • a suitable coupling reagent such as, for example, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide EDC, (1-[bis(dimethyl- amino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate HATU, (2- (1H-
  • the invention provides a method for preparing a compound of formula 16E: or a salt thereof, comprising converting a compound of formula 16D: or a salt thereof, to the compound of formula 16D.
  • the conversion can be carried out at any suitable temperature and can be carried out neat or in the presence of one or more solvents.
  • the conversion is carried out in a nonpolar aprotic solvent, such as, for example, dichloromethane, chloroform, or carbon tetrachloride.
  • the conversion is carried out at a temperature in the range from about -25 °C to about 50 °C.
  • the conversion is carried out at a temperature in the range from about 0 °C to about 50 °C.
  • the conversion is carried out in the presence of a suitable acid.
  • the acid is trifluoroacetic acid.
  • the invention provides a method for preparing a compound of formula 16:
  • the conversion can be carried out at any suitable temperature and can be carried out neat or in the presence of one or more solvents.
  • the conversion is carried out in a polar aprotic solvent, such as, for example, dimethylformamide, dichloromethane, or dimethylaminopyridine.
  • the conversion is carried out at a temperature in the range from about -25 °C to about 25 °C.
  • the conversion is carried out at a temperature in the range from about 0 °C to about 10 °C.
  • the conversion is carried out in the presence of a suitable base.
  • the base is a hindered amine base, such as, for example, diisopropylethylamine, trimethylamine, dimethylaminopyridine, or pyridine.
  • the conversion is carried out in the presence of a suitable coupling agent, such as, for example, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide EDC.
  • the conversion is carried out in the presence of a suitable hydroxybenzotriazole, N,N′- dicyclohexylcarbodiimide DCC, (1-[bis(dimethylamino)-methylene]-1H-1,2,3-triazolo[4,5- b]pyridinium 3-oxide hexafluorophosphate HATU, or propanephosphonic acid anhydride T3P).
  • a suitable hydroxybenzotriazole N,N′- dicyclohexylcarbodiimide DCC, (1-[bis(dimethylamino)-methylene]-1H-1,2,3-triazolo[4,5- b]pyridinium 3-oxide hexafluorophosphate HATU, or propanephosphonic acid anhydride T3P).
  • the compound of formula 16E or the salt thereof is converted to the compound of formula 16 or the salt thereof, by reacting the compound of formula 16E or the salt thereof with a compound of formula 11: or a salt thereof,
  • Red-Al (1.6 Kg, 4.75 mol, 60-70% solution in toluene) was added slowly maintaining the temperature below -5 to 0 °C °C.
  • the reaction mixture was then warmed to 25 °C to 30 °C and stirred for not less than 12 hours until completion of reaction as confirmed by UPLC (disappearance of compound 1-2).
  • UPLC disappearance of compound 1-2
  • NaOH solution 4.0 L
  • the reaction mixture was quenched by transferring into the cold 10% NaOH solution while maintaining the temperature below 30 °C. After completion of transfer, quench mixture allowed to stir for 3 hours and then layers allowed to separate. The organic layer was separated.
  • Example 3 Synthesis of Compound 5 To a solution of compound 4 (35.0 g, 9.8 mmol) in DCM (350 mL), trimethylamine TEA (14.87 g, 14.7 mmol) and DMAP (1.2 g, 1.0 mmol) were added at 20 °C to 30 °C. This mixture was cooled to 0 °C to 5 °C and DMTrCl (33.2 g, 9.8 mmol) was added. The reaction mixture allowed to stir at the same temperature for not less than 2 hours until completion of reaction as confirmed by UPLC. Water (350 mL) was added and mixture allowed to warm to 20 to 30 °C and stirred for 30 minutes. The aqueous layer was separated and extracted with DCM (70 mL).
  • Example 4 Synthesis of Compound 6 A solution of compound 5 (35.0 g, 5.3 mmol) in MeOH/Water (1:1, 700 mL) was cooled to 0 °C. LiOH.H 2 O (4.86 g, 11.6 mmol) was added and mixture stirred for not less than 1 hour until completion of reaction as confirmed by UPLC. Methanol was evaporated, water added and the mixture cooled to 0 to 5 °C. The mixture was neutralized to ⁇ pH 7.0 with sodium dihydrogen phosphate solution and then acidified to pH 6 to 6.5 using acetic acid while maintaining the temperature below 5 °C.
  • the contents were washed with 95 mL (5 V) of 1N HCl, 95 mL (5 V) of 8wt% NaHCO3 and 95 mL (5 V) of brine in a sequence. Then, 38 mL (2 V) of purified water was added to the organic layer and the contents were concentrated under 20 torr at 65 °C with a water bath. The process for azeotrope concentration was repeated 2 times with water (distillation with water removes impurities). After azeotrope concentration, the concentrate was diluted with 57 mL (3 V) of DCM and treated with 19 g (1 S) of Na2SO4. The contents were filtered and the waste was washed with 38 mL (2 V) of DCM.
  • the mixture was agitated at 60 to 65 °C for not less than 3 hours until completion of reaction as confirmed by UPLC.
  • the mixture was allowed to cool to 20 °C to 25 °C and sequentially washed with 8 wt% aq. NaHCO3 (2 x 60 mL), 1N HCl (120 mL), brine (120 mL), dried over Na2SO4 (120 g) and evaporated to dryness to give compound 10 (22.7 g, quantitative yield) as a light-yellow syrup. m/z 613.3 [M+H] + .
  • Example 7 Synthesis of Compound 11 To a solution of compound 10 (110 g, 179 mmol) in THF (100 mL), TFA (20.5 g, 179 mmol) was added. The mixture was degassed and purged with N 2 , twice. 10 wt % Pd/C (11 g) was charged and the mixture was degassed and purged with H 2 , twice. The mixture was allowed to agitate under H2 atmosphere (70 psi) for not less than 3 hours until completion of reaction as confirmed by UPLC. The mixture was degassed and purged with N 2 , filtered through a pad of celite.
  • Example 17 Synthesis of Compound 16-2 To a suspension of compound 16-1 (50 g, 236 mmol) in DCM (500 mL), oxalyl chloride (69 g, 543 mmol) and DMF (172 mg, 2.3 mmol) were sequentially charged with agitation while maintaining internal temperature 20 to 30 °C. The mixture was allowed to agitate 20°C to 30 °C for not less than 12 hours until completion of reaction as confirmed by disappearance of compound 16-1 by UPLC. The mixture is evaporated to dryness and the residue is taken into toluene. To the toluene solution were charged t-BuOH (52.5 g, 708mmol) and DMAP (66.3 g, 543 mmol).
  • Example 23 Synthesis of Compound 16 To a solution of compound 15 (40 g, 31.82 mmol) in DMF (400 mL), compound 15A (4.0 g, 14.32 mmol) and HBTU (14.5 g, 38.18 mmol) were added. The reaction mixture was cooled to 10 °C to 15 °C TEA (10.6 mL, 76.36 mmol) was added while maintaining internal temperature at 10 °C to 15 °C. The reaction mixture allowed to warm to 20 °C to 25 °C and stir for not less than 3 hours until completion of reaction as confirmed by UPLC. He reaction mixture was quenched by addition of water (400 mL) and Ethyl acetate (400 mL).
  • Example 25 Synthesis of Compound 16 A solution of compound 15D (1.6 g, 4.08 mmol) and compound 13 (10 g, 9.07 mmol) in DCM (100 mL) was cooled to 0 °C to 10 °C. TEA (1.84 g, 18.14 mmol) and T3P (10.34 mL, 16.3 mmol, 50% solution in ethyl acetate) were charged sequentially with agitation at 0-10 °C.
  • the reaction mixture was agitated at 25 °C to 35 °C for not less than 6 hours until completion of reaction as confirmed by UPLC.
  • the reaction was quenched by addition of water (200 mL).
  • the aqueous layer was separated and extracted with DCM (50 mL).
  • the DCM layers were pooled and washed sequentially with saturated aq.NaHCO3 (200 mL), 1.0 N HCl (200 mL), 10% aq. NaCl solution (200 mL), then dried over Na2SO4 (25 g) and evaporated to about 20 g. MTBE (50 mL) was added and evaporated to complete dryness and further dried in vacuum at 45 °C.
  • Example 27 Synthesis of Compound 18 To a solution of compound 17 (1.0 g, 0.39 mmol) in DCM (25 mL), compound 6 (0.29g, 0.44 mmol), HBTU (186 mg, 0.49 mmol), were added and mixture cooled to 15 °C to 25 °C. DIPEA (151 mg, 1.17 mmol) was added maintaining the internal temperature at 15 °C to 25 °C and then allowed to stir at 20 °C to 25 °C for not less than 2.5 hours until completion of reaction as confirmed by UPLC. The reaction mixture diluted with DCM (5 mL) washed with water (10 mL), aq.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Laminated Bodies (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention provides synthetic processes and synthetic intermediate compounds that can be used to prepare therapeutic conjugates. The invention also provides methods for treating HBV and/or HDV infection in a human by administering a therapeutic conjugate prepared by the synthetic methods of the invention.

Description

SYNTHETIC PROCESSES AND INTERMEDIATES CROSS-REFERENCE TO RELATED APPLICATION(S) This patent application claims the benefit of priority of U.S. application serial No. 62/951,836, filed December 20, 2019, which application is herein incorporated by reference. BACKGROUND Hepatitis B virus (HBV) is a member of the Hepadnavirus family. Infection of humans with HBV can cause an infectious inflammatory illness of the liver. Infected individuals may not exhibit symptoms for many years. It is estimated that about a third of the world population has been infected at one point in their lives, including 350 million who are chronic carriers. Hepatitis D virus (HDV) is a small circular enveloped RNA virus that can propagate only in the presence of the hepatitis B virus (HBV). In particular, HDV requires the HBV surface antigen protein to propagate itself. Infection with both HBV and HDV results in more severe complications compared to infection with HBV alone. In combination with hepatitis B virus, hepatitis D has the highest mortality rate of all the hepatitis infections. International Patent Application Publication Number WO 2018/191278 describes conjugates that are useful to target siRNA to the liver that are suitable for treating, e.g., HBV and/or HDV. Currently there is a need for synthetic processes and synthetic intermediates that can be used to prepare such conjugates. SUMMARY In one aspect the invention provides synthetic processes and synthetic intermediate compounds that can be used to prepare therapeutic conjugates. The invention also provides a method for treating HBV and/or HDV infection in a human by administering a therapeutic conjugate prepared by a method of the invention. The invention also provides a method for treating HBV and/or HDV infection in a human subject comprising administering to the human subject, a therapeutically effective amount of a therapeutic conjugate prepared by a methods of the invention, and a second therapeutic agent that is useful for treating HBV and/or HDV. The invention also provides a compound prepared by a method of the invention. The invention also provides a therapeutic conjugate prepared by a method of the invention for use in medical therapy. The invention also provides a therapeutic conjugate prepared by a method of the invention for the prophylactic or therapeutic treatment of HBV and/or HDV, optionally in combination with another therapeutic agent. The invention also provides the use of a therapeutic conjugate prepared by a method of the invention to prepare a medicament for the treatment of HBV and/or HDV, optionally in combination with another therapeutic agent. DETAILED DESCRIPTION OF THE INVENTION The following definitions are used, unless otherwise described. The term "alkyl", by itself or as part of another substituent, means, unless otherwise stated, a straight or branched chain hydrocarbon radical, having the number of carbon atoms designated (i.e., C1-8 means one to eight carbons). Examples include (C1-C8)alkyl, (C2-C8)alkyl,C1-C6)alkyl, (C2-C6)alkyl and (C3-C6)alkyl. Examples of alkyl groups include methyl, ethyl, n- propyl, iso-propyl, n-butyl, t-butyl, iso-butyl, sec-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, and and higher homologs and isomers. As used herein, the term "protecting group" refers to a substituent that is commonly employed to block or protect a particular functional group on a compound. For example, an "amino-protecting group" is a substituent attached to an amino group that blocks or protects the amino functionality in the compound. Suitable amino-protecting groups include acetyl, trifluoroacetyl, t-butoxycarbonyl (BOC), benzyloxycarbonyl (CBZ) and 9- fluorenylmethylenoxycarbonyl (Fmoc). Similarly, a "hydroxy-protecting group" refers to a substituent of a hydroxy group that blocks or protects the hydroxy functionality. Suitable protecting groups include acetyl and silyl. A "carboxy-protecting group" refers to a substituent of the carboxy group that blocks or protects the carboxy functionality. Common carboxy- protecting groups include phenylsulfonylethyl, cyanoethyl, 2-(trimethylsilyl)ethyl, 2- (trimethylsilyl)ethoxymethyl, 2-(p-toluenesulfonyl)ethyl, 2-(p-nitrophenylsulfenyl)ethyl, 2- (diphenylphosphino)-ethyl, nitroethyl and the like. For a general description of protecting groups and their use, see P.G.M. Wuts and T.W. Greene, Greene's Protective Groups in Organic Synthesis 4th edition, Wiley-Interscience, New York, 2006. As used herein a wavy line “ ” that intersects a bond in a chemical structure indicates the point of attachment of the bond that the wavy bond intersects in the chemical structure to the remainder of a molecule. When a bond in a compound formula herein is drawn in a non-stereochemical manner (e.g. flat), the atom to which the bond is attached includes all stereochemical possibilities. When a bond in a compound formula herein is drawn in a defined stereochemical manner (e.g. bold, bold-wedge, dashed or dashed-wedge), it is to be understood that the atom to which the stereochemical bond is attached is enriched in the absolute stereoisomer depicted unless otherwise noted. In one embodiment, the compound may be at least 51% the absolute stereoisomer depicted. In another embodiment, the compound may be at least 60% the absolute stereoisomer depicted. In another embodiment, the compound may be at least 80% the absolute stereoisomer depicted. In another embodiment, the compound may be at least 90% the absolute stereoisomer depicted. In another embodiment, the compound may be at least 95 the absolute stereoisomer depicted. In another embodiment, the compound may be at least 99% the absolute stereoisomer depicted. Capsid Inhibitors As described herein the term “capsid inhibitor” includes compounds that are capable of inhibiting the expression and/or function of a capsid protein either directly or indirectly. For example, a capsid inhibitor may include, but is not limited to, any compound that inhibits capsid assembly, induces formation of non-capsid polymers, promotes excess capsid assembly or misdirected capsid assembly, affects capsid stabilization, and/or inhibits encapsidation of RNA. Capsid inhibitors also include any compound that inhibits capsid function in a downstream event(s) within the replication process (e.g., viral DNA synthesis, transport of relaxed circular DNA (rcDNA) into the nucleus, covalently closed circular DNA (cccDNA) formation, virus maturation, budding and/or release, and the like). For example, in certain embodiments, the inhibitor detectably inhibits the expression level or biological activity of the capsid protein as measured, e.g., using an assay described herein. In certain embodiments, the inhibitor inhibits the level of rcDNA and downstream products of viral life cycle by at least 5%, at least 10%, at least 20%, at least 50%, at least 75%, or at least 90%. The term capsid inhibitor includes compounds described in International Patent Applications Publication Numbers WO2013006394, WO2014106019, and WO2014089296, including the following compounds:
Figure imgf000005_0001
. The term capsid inhibitor also includes the compounds Bay-41-4109 (see International Patent Application Publication Number WO/2013/144129), AT-61 (see International Patent Application Publication Number WO/1998/33501; and King, RW, et al., Antimicrob Agents Chemother., 1998, 42, 12, 3179–3186), DVR-01 and DVR-23 (see International Patent Application Publication Number WO 2013/006394; and Campagna, MR, et al., J. of Virology, 2013, 87, 12, 6931, and pharmaceutically acceptable salts thereof:
Figure imgf000005_0002
The term capsid inhibitor also includes:
Figure imgf000005_0003
and a pharmaceutically acceptable salt thereof. sAg Secretion Inhibitors/RNA Destabilizers As described herein the term “sAg secretion inhibitor” includes compounds that are capable of inhibiting, either directly or indir tl th etion of sAg (S, M and/or L surface antigens) bearing subviral particles and/or DNA containing viral particles from HBV-infected cells. As used herein, “sAg secretion inhibitors” are also known as “RNA destabilizers”, and these terms are used interchangeably. For example, in certain embodiments, the inhibitor detectably inhibits the secretion of sAg as measured, e.g., using assays known in the art or described herein, e.g., ELISA assay or by Western Blot. In certain embodiments, the inhibitor inhibits the secretion of sAg by at least 5%, at least 10%, at least 20%, at least 50%, at least 75%, or at least 90%. In certain embodiments, the inhibitor reduces serum levels of sAg in a patient by at least 5%, at least 10%, at least 20%, at least 50%, at least 75%, or at least 90%. The term sAg secretion inhibitor includes compounds described in United States Patent Number 8,921,381, as well as compounds described in United States Patent Application Publication Numbers 2015/0087659 and 2013/0303552. For example, the term includes the compounds PBHBV-001 and PBHBV-2-15, and pharmaceutically acceptable salts thereof:
Figure imgf000006_0001
. Specific embodiments of the invention are described below. In one embodiment, the invention provides a method for preparing a compound of formula 1:
Figure imgf000006_0002
comprising reacting a compound of formula 1-1:
Figure imgf000006_0003
with a compound of formula 1-2:
Figure imgf000007_0001
at a temperature of 40 °C or greater to provide the compound of formula 1. The reaction can be carried out neat or in the presence of one or more solvents. In one embodiment, the invention is carried out in a polar aprotic solvent, such as, for example, tetrahydrofuran, 1,2-dichloroethene, methyltetrahydrofuran, toluene, acetonitrile, dimethoxyethane, or carbon tetrachloride. In one embodiment, the reaction is carried out at a temperature in the range from about 0 °C to about 100 °C. In another embodiment, the reaction is carried out at a temperature of 60 °C or greater. In another embodiment, the reaction is carried out at a temperature in the range from about 60 °C to about 80 °C. In one embodiment, the invention provides a method for preparing a crystalline form of compound 3:
Figure imgf000007_0002
comprising converting a compound of formula 1:
Figure imgf000007_0003
to the crystalline form of compound 3 without using column chromatography during the conversion. In one embodiment, the compound can be crystallized from a solvent that comprises dichloromethane or ethyl acetate. In another embodiment, the compound is crystallized from dichloromethane or ethyl acetate. In one embodiment, the invention provides a crystalline form of compound 3:
Figure imgf000007_0004
. In one embodiment, the invention provides a method for preparing a compound of formula 9:
Figure imgf000008_0001
wherein R9 is an optionally substituted benzyloxycarbonyl group, comprising converting a compound of formula 8:
Figure imgf000008_0002
or a salt thereof to the compound of formula 9. The conversion can be carried out at any suitable temperature and can be carried out neat or in the presence of one or more solvents. In one embodiment of the invention the conversion is carried out in a polar or nonpolar aprotic solvent, such as, for example, dichloromethane, chloroform, tetrahydrofuran, methyltetrahydrofuran, carbon tetrachloride, acetonitrile, pyridine, dimethylformamide, dimethylacetamide, or toluene. In one embodiment, the conversion is carried out at a temperature in the range from about 0 °C to about 100 °C. In another embodiment, the conversion is carried out at a temperature in the range from about 15 °C to about 25 °C. In one embodiment, R9 is benzyloxycarbonyl or nitrobenzyloxycarbonyl. In one embodiment, the compound of formula 8 is converted to the compound of formula 9 by treating the compound of formula 8 with benzyloxycarbonyl chloride in a suitable solvent in the presence of a suitable base. In one embodiment, the base is an amine base, such as, for example, trimethylamine, triethylamine, pyridine, dimethylaminopyridine, diisopropylethylamine, or tripropyl amine. In one embodiment, the invention provides a method for preparing a compound of formula 10:
Figure imgf000008_0003
wherein R9 is an optionally substituted benzyloxycarbonyl group, comprising converting a corresponding compound of formula 9:
Figure imgf000008_0004
to the compound of formula 10. The conversion can be carried out at any suitable temperature and can be carried out neat or in the presence of one or more solvents. In one embodiment, the conversion provides the compound of formula 10 as at least about 85%, 90%, or 95% the beta- isomer. In one embodiment of the invention the conversion is carried out in a nonpolar aprotic solvent, such as, for example, dichloroethane, dichloromethane, acetonitrile, methyltetrahydro- furan, tetrahydrofuran, dimethoxyethane, or toluene. In one embodiment, the conversion is carried out at a temperature in the range from about 0 °C to about 100 °C. In another embodiment, the conversion is carried out at a temperature in the range from about 80 °C to about 85 °C. In another embodiment, the conversion is carried out at a temperature in the range from about 35 °C to about 45 °C. In another embodiment, the conversion is carried out at a temperature in the range from about 45 °C to about 55 °C. In another embodiment, the conversion is carried out at a temperature in the range from about 55 °C to about 65 °C. In another embodiment, the conversion is carried out at a temperature that optimizes the beta:alpha ratio of the product. In one embodiment, R9 is benzyloxycarbonyl or nitrobenzyloxycarbonyl. In one embodiment, the compound of formula 9 is converted to the compound of formula 10 by treatment with a compound of formula 7:
Figure imgf000009_0001
in the presence of a suitable catalyst and a suitable solvent. In one embodiment, the catalyst is Sc(OTf)3, trimethylsilyl trifluoromethanesulfonate, zinc chloride, or 4A molecular sieves. In one embodiment, the invention provides a method for preparing a compound of formula 10:
Figure imgf000009_0002
wherein R9 is an optionally substituted benzyloxycarbonyl group, comprising converting a compound of formula 8:
Figure imgf000009_0003
or a salt thereof to a corresponding compound of formula 9;
Figure imgf000010_0001
and subsequently converting the corresponding compound of formula 9 to the compound of formula 10, without purifying the compound of formula 9 by chromatography. In one embodiment, the invention provides a method for preparing a salt of formula 11:
Figure imgf000010_0002
comprising treating a compound of formula 10:
Figure imgf000010_0003
wherein R9 is an optionally substituted benzyloxycarbonyl group, with hydrogen and trifluoroacetic acid in the presence of a suitable catalyst and in the presence of a suitable solvent. In one embodiment, the suitable catalyst comprises palladium on carbon. In one embodiment, the suitable solvent comprises tetrahydrofuran. The reaction can be carried out at any suitable temperature. In one embodiment, the reaction is carried out at a temperature in the range from about 0 °C to about 50 °C. In another embodiment, the reaction is carried out at a temperature in the range from about 20 °C to about 25 °C. In one embodiment, R9 is benzyloxycarbonyl or nitrobenzyloxycarbonyl. In one embodiment, the invention provides a method for preparing a compound of formula 15D:
Figure imgf000010_0004
or a salt thereof, comprising converting a compound of formula 15C:
Figure imgf000010_0005
wherein each R15 is a (C1-C6)alkyl, to the compound of formula 15D or the salt thereof. The conversion can be carried out at any suitable temperature and can be carried out neat or in the presence of one or more solvents. In one embodiment of the invention, the conversion is carried out in a polar protic solvent, such as, for example, methanol, ethanol, tetrahydrofuran, and/or water. In one embodiment, the conversion is carried out at a temperature in the range from about 0 °C to about 100 °C. In another embodiment, the conversion is carried out at a temperature in the range from about 15 °C to about 25 °C. In one embodiment, the conversion is carried out in the presence of a suitable base, such as, for example, sodium hydroxide, lithium hydroxide, or potassium hydroxide. In one embodiment, the invention provides a method for preparing a compound of formula 15C:
Figure imgf000011_0001
wherein each R15 is a (C1-C6)alkyl, comprising reacting a compound of formula 15A:
Figure imgf000011_0002
or a salt thereof, with a corresponding compound of formula 15B:
Figure imgf000011_0003
or a salt thereof, to provide the compound of formula 15C. The reaction can be carried out at any suitable temperature and can be carried out neat or in the presence of one or more solvents. In one embodiment of the invention the reaction is carried out in a polar aprotic solvent, such as, for example, dimethylformamide, dichloromethane, 1,2-dichloroethane, or dimethylacetamide. In one embodiment, the reaction is carried out at a temperature in the range from about 0 °C to about 50 °C. In another embodiment, the reaction is carried out at a temperature in the range from about5 °C to about 10 °C. In one embodiment, the reaction is carried out in the presence of a suitable base. In one embodiment, the base is a hindered amine base, such as, for example, diisopropylethylamine, trimethylamine, pyridine, or dimethylaminopyridine. In one embodiment, the reaction is carried out in the presence of a suitable coupling agent, such as, for example, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide EDC, N,N′-dicyclohexyl- carbodiimide DCC, (1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3- oxide hexafluorophosphate HATU, (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate HBTU, or propanephosphonic acid anhydride T3P). In one embodiment, the invention provides a method for preparing a compound of formula 13A:
Figure imgf000012_0001
wherein each R15 is a (C1-C6)alkyl, comprising converting a corresponding compound of formula 15C:
Figure imgf000012_0002
wherein each R15 is a (C1-C6)alkyl, to the compound of formula 13A. The conversion can be carried out at any suitable temperature and can be carried out neat or in the presence of one or more solvents. In one embodiment of the invention, the conversion is carried out in a polar protic solvent, such as, for example, methanol, ethyl acetate, tetrahydrofuran, methyltetrahydrofuran, or ethanol. In one embodiment, the conversion is carried out at a temperature in the range from about 0 °C to about 100 °C. In another embodiment, the conversion is carried out at a temperature in the range from about 15 °C to about 25 °C. In one embodiment, the conversion is carried out in the presence of a suitable catalyst, such as, for example, palladium on carbon or Pd(OH)2. In one embodiment, the invention provides a method for preparing a compound of formula 13B:
Figure imgf000012_0003
wherein each R15 is a (C1-C6)alkyl and T is an optionally substituted triphenylmethyl group, comprising converting a corresponding com d f f mula 13A:
Figure imgf000013_0001
to the compound of formula 13B. The conversion can be carried out at any suitable temperature and can be carried out neat or in the presence of one or more solvents. In one embodiment of the invention, the conversion is carried out in a nonpolar aprotic solvent, such as, for example, dichloromethane, 1,2-dichloroethane, dimethylformamide, or dimethylacetamide. In one embodiment, the conversion is carried out at a temperature in the range from about -78 °C to about 100 °C. In another embodiment, the conversion is carried out at a temperature in the range from about 0 °C to about 30 °C. In one embodiment, the conversion is carried out in the presence of a suitable coupling agent, such as, for example, 1-ethyl-3-(3-dimethylamino- propyl)carbodiimide EDC, N,N′-dicyclohexylcarbodiimide DCC, (1-[bis(dimethylamino)- methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate HATU, (2-(1H- benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate HBTU, or propanephosphonic acid anhydride T3P). In one embodiment, the compound of formula 13A is converted to the compound of formula 13B, by treating the compound of formula 13A with a corresponding compound of formula 6:
Figure imgf000013_0002
or a salt thereof, wherein DMTr is 4,4-dimethoxytriphenylmethyl under suitable amide forming conditions. In one embodiment, the compound of formula 13A is treated with the compound of formula:
Figure imgf000013_0003
in dichloromethane at a temperature in the range from about 0 °C to about 30 °C in the presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide. In one embodiment, the invention provides a method for preparing a compound of formula 13C:
Figure imgf000014_0001
comprising converting a compound of formula 13B:
Figure imgf000014_0002
wherein each R15 is a (C1-C6)alkyl and T is an optionally substituted triphenylmethyl group, to the compound of formula 13C. The conversion can be carried out at any suitable temperature and can be carried out neat or in the presence of one or more solvents. In one embodiment of the invention, the conversion is carried out in a polar protic solvent, such as, for example, methanol, ethanol, tetrahydrofuran, and/or water. In one embodiment, the conversion is carried out at a temperature in the range from about 0 °C to about 100 °C. In another embodiment, the conversion is carried out at a temperature in the range from about 20 °C to about 40 °C. In one embodiment, the conversion is carried out in the presence of a suitable base, such as, for example, potassium hydroxide, lithium hydroxide, or sodium hydroxide. In one embodiment, the compound of formula 13B is converted to the compound of formula 13C by treatment with potassium hydroxide in a solvent comprising methanol and water. In one embodiment, the invention provides a method for preparing a crystalline potassium salt of a compound of formula 13CC:
Figure imgf000014_0003
comprising treating a compound of formula 13CC or a salt thereof with potassium hydroxide in methanol. In one embodiment, the crystalline potassium salt of a compound of formula 13CC can be prepared as described in Example 30. In one embodiment, the invention provides a method for preparing a compound of formula 11B:
Figure imgf000015_0001
comprising converting a compound of formula 11A:
Figure imgf000015_0002
or a salt thereof, to the compound of formula 11B. The conversion can be carried out at any suitable temperature and can be carried out neat or in the presence of one or more solvents. In one embodiment of the invention the conversion is carried out in a nonpolar aprotic solvent, such as, for example, dichloromethane, 1,2-dichloroethane, methyltetrahydrofuran, tetrahydrofuran, dimethylformamide, or dimethylacetamide. In one embodiment, the conversion is carried out at a temperature in the range from about 0 °C to about 100 °C. In another embodiment, the conversion is carried out at a temperature in the range from about 5 °C to about 30 °C. In one embodiment, the compound of formula 11A is converted to the compound of formula 11B by treating the compound of formula 11A or the salt thereof with 1-ethyl-3-(3- dimethylaminopropyl)carbodiimide EDC, N,N′-dicyclohexylcarbodiimide DCC, (1- [bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate HATU, (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate HBTU, or propanephosphonic acid anhydride T3P) in dichloromethane. In one embodiment, the invention provides a method for preparing a compound of formula 12:
Figure imgf000016_0001
comprising converting a compound of formula 11B:
Figure imgf000016_0002
to the compound of formula 12. The conversion can be carried out at any suitable temperature and can be carried out neat or in the presence of one or more solvents. In one embodiment of the invention the conversion is carried out in a nonpolar aprotic solvent, such as, for example, dichloromethane, 1,2-dichloroethane, methyltetrahydrofuran, tetrahydrofuran, dimethylformamide, or dimethylacetamide. In one embodiment, the conversion is carried out at a temperature in the range from about 0 °C to about 50 °C. In another embodiment, the conversion is carried out at a temperature in the range from about 0 °C to about 30 °C. In one embodiment, the conversion is carried out in the presence of a suitable base. In one embodiment, the base is a hindered amine base, such as, for example, diisopropylethylamine, trimethylamine, dimethylaminopyridine, or pyridine. In one embodiment, the compound of formula 11B is converted to the compound of formula 12 by treating the compound of formula 11B with a compound of formula 11:
Figure imgf000016_0003
or a salt thereof, in the presence of a suitable base and a suitable solvent. In one embodiment, the compound of formula 11B is converted to the compound of formula 12 by treating the compound of formula 11B with the trifloroacetic acid salt of a compound of formula 11:
Figure imgf000017_0001
in the presence of diisopropylethylamine and a solvent that comprises dichloromethane. In one embodiment, the invention provides a method for preparing a compound of formula 13:
Figure imgf000017_0002
or a salt thereof, comprising reducing a compound of formula 12:
Figure imgf000017_0003
to provide the compound of formula 13 or the salt thereof. The reduction can be carried out at any suitable temperature and can be carried out neat or in the presence of one or more solvents. In one embodiment of the invention the reduction is carried out in a polar aprotic solvent, such as, for example, tetrahydrofuran, methyltetrahydrofuran, or ethyl acetate. In one embodiment, the reduction is carried out at a temperature in the range from about 0 °C to about 50 °C. In another embodiment, the reduction is carried out at a temperature in the range from about 0 °C to about 30 °C. In one embodiment, the reduction is carried out in the presence of a suitable catalyst, such as, for example, palladium on carbon. In one embodiment, the compound of formula 13 or the salt thereof, is a trifluoroacetic acid salt of the following formula:
Figure imgf000018_0001
. In one embodiment, the invention provides a method for preparing a compound of formula 14:
Figure imgf000018_0003
comprising converting a compound of formula 13:
Figure imgf000018_0002
or a salt thereof to the compound of formula 14. The conversion can be carried out at any suitable temperature and can be carried out neat or in the presence of one or more solvents. In one embodiment of the invention the conversion is carried out in a nonpolar aprotic solvent, such as, for example, dichloromethane, 1,2-dichloroethane, methyltetrahydrofuran, tetrahydrofuran, dimethylformamide, or dimethylacetamide. In one embodiment, the conversion is carried out at a temperature in the range from about -78 °C to about 25 °C. In another embodiment, the conversion is carried out at a temperature in the range from about -25 °C to about 30 °C. In one embodiment, the conversion is carried out in the presence of a suitable base. In one embodiment, the base is an amine base, such as, for example, trimethylamine, triethylamine, diisopropylethylamine, dimethylaminopyridine, pyridine, or tripropylamine. In one embodiment, the conversion is carried out in the presence of a suitable coupling reagent, such as, for example, propanephosphonic acid anhydride. In one embodiment, the compound of formula 13 is converted to the compound of formula 14, by treating the compound of formula 13 with a compound of formula:
Figure imgf000019_0001
or a salt thereof, in a solvent comprising dichloromethane in the presence of a coupling agent, such as, for example, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide EDC, (1- [bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate HATU, (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate HBTU, or propanephosphonic acid anhydride T3P, at a temperature n the range from about -15 °C to about 15 °C. In one embodiment, the invention provides a method for preparing a compound of formula 16:
Figure imgf000019_0002
wherein R16 is an amine protecting group, comprising converting a compound of formula 13:
Figure imgf000019_0003
or a salt thereof, to the compound of formula 16. The conversion can be carried out at any suitable temperature and can be carried out neat or in the presence of one or more solvents. In one embodiment of the invention the conversion is carried out in a nonpolar aprotic solvent, such as, for example, dichloromethane, 1,2-dichloroethane, methyltetrahydrofuran, tetrahydrofuran, dimethylformamide, or dimethylacetamide. In one embodiment, the conversion is carried out at a temperature in the range from about -78 °C to about 50 °C. In another embodiment, the conversion is carried out at a temperature in the range from about -25 °C to about 50 °C. In one embodiment, the conversion is carried out in the presence of a suitable base. In one embodiment, the base is an amine base, such as, for example, trimethylamine, triethylamine, or tripropylamine, diisopropylethylamine, dimethylaminopyridine, or pyridine. In one embodiment, the conversion is carried out in the presence of a suitable coupling reagent, such as, for example, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide EDC, (1- [bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate HATU, (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate HBTU, or propanephosphonic acid anhydride T3P. In one embodiment, the compound of formula 13 or the salt thereof is converted to the compound of formula 16, by treating the compound of formula 13 with a corresponding compound of formula 15DD:
Figure imgf000020_0001
wherein R16 is an amine protecting group, or a salt thereof, under suitable coupling conditions. In one embodiment, a trifluoroacetic acid salt of a compound of formula 13:
Figure imgf000020_0002
is treated with a compound of formula 15D wherein R16 is benzyloxycarbonyl:
Figure imgf000021_0003
under suitable coupling conditions to provide a compound of formula 16 wherein R16 is benzyloxycarbonyl. In one embodiment, the compound of formula 13 is treated with the compound of formula 15D or 15DD in the presence of propanephosphonic acid anhydride, trimethylamine, and a solvent comprising dichloromethane to provide the compound of formula 16. In one embodiment, the invention provides a method for preparing a compound of formula 18:
Figure imgf000021_0001
wherein R18 is a suitable protecting group, comprising converting a compound of formula 13:
Figure imgf000021_0002
or a salt thereof, to the compound of formula 18. The conversion can be carried out at any suitable temperature and can be carried out neat or in the presence of one or more solvents. In one embodiment of the invention the conversion is carried out in a nonpolar aprotic solvent, such as, for example, dichloromethane, 1,2-dichloroethane, methyltetrahydrofuran, tetrahydrofuran, dimethylformamide, or dimethylacetamide. In one embodiment, the conversion is carried out at a temperature in the range from about -78 °C to about 50 °C. In another embodiment, the conversion is carried out at a temperature in the range from about -25 °C to about 50 °C. In one embodiment, the conversion is carried out in the presence of a suitable base. In one embodiment, the base is an amine base, such as, for example, trimethylamine, triethylamine, or tripropylamine, diisopropylethylamine, dimethylaminopyridine, or pyridine. In one embodiment, the conversion is carried out in the presence of a suitable coupling reagent, such as, for example, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide EDC, (1- [bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate HATU, (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate HBTU, or propanephosphonic acid anhydride T3P. In one embodiment, the compound of formula 13 or the salt thereof is converted to the compound of formula 18, by treating the compound of formula 13 or the salt thereof with a compound of formula 13CCC:
Figure imgf000022_0001
wherein R18 is a suitable protecting group, or a salt thereof, under suitable coupling conditions. In one embodiment, a trifluoroacetic acid salt of a compound of formula 13:
Figure imgf000022_0002
is treated with a compound of formula 13CCC, wherein R18 is 4,4-dimethoxytriphenylmethyl under suitable coupling conditions to provide a compound of formula 18:
Figure imgf000023_0001
wherein R18 is 4,4-dimethoxytriphenylmethyl. In one embodiment, the compound of formula 13 is treated with the compound of formula 13CCC in the presence of propanephosphonic acid anhydride, trimethylamine, and a solvent comprising dichloromethane to provide the compound of formula 18. In one embodiment, the invention provides a method for preparing a compound of formula 16-2:
Figure imgf000023_0002
comprising converting a compound of formula 16-1:
Figure imgf000023_0003
or a salt thereof, to the compound of formula 16-2. The conversion can be carried out at any suitable temperature and can be carried out neat or in the presence of one or more solvents. In one embodiment of the invention, the conversion is carried out in a nonpolar aprotic solvent, such as, for example, dichloromethane, 1,2-dichloroethane, chloroform, or carbon tetrachloride. In one embodiment, the conversion is carried out at a temperature in the range from about -78 °C to about 100 °C. In another embodiment th ion is carried out at a temperature in the range from about -0 °C to about 30 °C. In one embodiment, the conversion is carried out by activating the carboxylic acid groups in the compound of formula 16-1, for example, by treating the compound of formula 16-1 with oxalyl chloride, and treating the resulting carboxylic acid chloride groups with tert-butanol to provide the compound of formula 16-2. In one embodiment, the invention provides a method for preparing a compound of formula 16-3:
Figure imgf000024_0001
comprising converting a compound of formula 16-2:
Figure imgf000024_0002
to the compound of formula 16-3. The conversion can be carried out at any suitable temperature and can be carried out neat or in the presence of one or more solvents. In one embodiment of the invention the conversion is carried out in a polar protic solvent, such as, for example, methanol or ethanol. In one embodiment, the reaction is carried out at a temperature in the range from about -78 °C to about 50 °C. In another embodiment, the conversion is carried out at a temperature in the range from about -0 °C to about 50 °C. In one embodiment, the conversion is carried out in the presence of a suitable catalyst, such as, for example, palladium on carbon. In one embodiment, the invention provides a method for preparing a compound of formula 16-4: comprising converting a compound of formula 16-3:
Figure imgf000025_0001
to the compound of formula 16-4. The conversion can be carried out at any suitable temperature and can be carried out neat or in the presence of one or more solvents. In one embodiment of the invention the conversion is carried out in a nonpolar aprotic solvent, such as, for example, dichloromethane, 1,2-dichloroethane, methyltetrahydrofuran, tetrahydrofuran, dimethylformamide, or dimethylacetamide. In one embodiment, the conversion is carried out at a temperature in the range from about -78 °C to about 50 °C. In another embodiment, the conversion is carried out at a temperature in the range from about -0 °C to about 50 °C. In one embodiment, the conversion is carried out in the presence of a suitable base. In one embodiment, the base is an amine base, such as, for example, trimethylamine, triethylamine, or tripropylamine, diisopropylethylamine, dimehylaminopyridine, or pyridine. In one embodiment, the conversion is carried out in the presence of a suitable coupling reagent, such as, for example, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide EDC, (1-[bis(dimethylamino)methylene]-1H- 1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate HATU, (2-(1H-benzotriazol-1-yl)- 1,1,3,3-tetramethyluronium hexafluorophosphate HBTU, or propanephosphonic acid anhydride T3P. In one embodiment, the invention provides a method for preparing a compound of formula 16-5:
Figure imgf000025_0002
or a salt thereof, comprising converting a compound of formula 16-4:
Figure imgf000026_0001
to the compound of formula 16-5. The conversion can be carried out at any suitable temperature and can be carried out neat or in the presence of one or more solvents. In one embodiment of the invention the conversion is carried out in a polar protic solvent, such as, for example, methanol, ethanol, tetrahydrofuran, or ethyl acetate. In one embodiment, the conversion is carried out at a temperature in the range from about -78 °C to about 50 °C. In another embodiment, the conversion is carried out at a temperature in the range from about -0 °C to about 50 °C. In one embodiment, the conversion is carried out in the presence of a suitable catalyst, such as, for example, palladium on carbon. In one embodiment, the invention provides a method for preparing a compound of formula 16D:
Figure imgf000026_0002
or a salt thereof, comprising converting a compound of formula 16-5:
Figure imgf000027_0001
to the compound of formula 16D. The conversion can be carried out at any suitable temperature and can be carried out neat or in the presence of one or more solvents. In one embodiment of the invention the conversion is carried out in a nonpolar aprotic solvent, such as, for example, dichloromethane, 1,2-dichloroethane, methyltetrahydrofuran, tetrahydrofuran, dimethylformamide, or dimethylacetamide. In one embodiment, the conversion is carried out at a temperature in the range from about -78 °C to about 50 °C. In another embodiment, the conversion is carried out at a temperature in the range from about 0 °C to about 50 °C. In one embodiment, the conversion is carried out in the presence of a suitable base. In one embodiment, the base is an amine base, such as, for example, trimethylamine, triethylamine, or tripropylamine, diisopropylethylamine, dimethylaminopyridine, or pyridine. In one embodiment, the conversion is carried out in the presence of a suitable coupling reagent, such as, for example, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide EDC, (1-[bis(dimethyl- amino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate HATU, (2- (1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate HBTU, or propanephosphonic acid anhydride T3P. In one embodiment, the invention provides a method for preparing a compound of formula 16E:
Figure imgf000027_0002
or a salt thereof, comprising converting a compound of formula 16D:
Figure imgf000028_0001
or a salt thereof, to the compound of formula 16D. The conversion can be carried out at any suitable temperature and can be carried out neat or in the presence of one or more solvents. In one embodiment of the invention the conversion is carried out in a nonpolar aprotic solvent, such as, for example, dichloromethane, chloroform, or carbon tetrachloride. In one embodiment, the conversion is carried out at a temperature in the range from about -25 °C to about 50 °C. In another embodiment, the conversion is carried out at a temperature in the range from about 0 °C to about 50 °C. In one embodiment, the conversion is carried out in the presence of a suitable acid. In one embodiment, the acid is trifluoroacetic acid. In one embodiment, the invention provides a method for preparing a compound of formula 16:
Figure imgf000029_0001
or a salt thereof, comprising converting a compound of formula 16E:
Figure imgf000029_0002
or a salt thereof, to the compound of formula 16. The conversion can be carried out at any suitable temperature and can be carried out neat or in the presence of one or more solvents. In one embodiment of the invention the conversion is carried out in a polar aprotic solvent, such as, for example, dimethylformamide, dichloromethane, or dimethylaminopyridine. In one embodiment, the conversion is carried out at a temperature in the range from about -25 °C to about 25 °C. In another embodiment, the conversion is carried out at a temperature in the range from about 0 °C to about 10 °C. In one embodiment, the conversion is carried out in the presence of a suitable base. In one embodiment, the base is a hindered amine base, such as, for example, diisopropylethylamine, trimethylamine, dimethylaminopyridine, or pyridine. In one embodiment, the conversion is carried out in the presence of a suitable coupling agent, such as, for example, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide EDC. In one embodiment, the conversion is carried out in the presence of a suitable hydroxybenzotriazole, N,N′- dicyclohexylcarbodiimide DCC, (1-[bis(dimethylamino)-methylene]-1H-1,2,3-triazolo[4,5- b]pyridinium 3-oxide hexafluorophosphate HATU, or propanephosphonic acid anhydride T3P). In one embodiment, the compound of formula 16E or the salt thereof is converted to the compound of formula 16 or the salt thereof, by reacting the compound of formula 16E or the salt thereof with a compound of formula 11:
Figure imgf000030_0001
or a salt thereof, under suitable coupling conditions. Compounds of formula 16 and formula 18 can be used to prepare therapeutic conjugates, including the corresponding therapeutic conjugates described in International Patent Application Publication Number WO 2018/191278. The invention will now be isllustrated by the following non-limiting examples. Examples Scheme 1
Figure imgf000030_0002
For Compounds 1-6, the bold-wedge bonds indicate a cis-isomer, not absolute stereochemistry. The invention provides Compounds 1-6 having both cis-configurations. When Compounds 1-6 are incorporated into other compounds herein, the bold-wedge bonds from Compounds 1-6 indicate a cis-conformation, while any other bold, bold-wedge, dashed or dashed-wedge bonds therein indicate absolute stereochemistry. Example 1. Synthesis of Compound 3
Figure imgf000031_0001
To a solution of compound 1-1 (200 g, 1.58 mol) in 2-MeTHF (2.4 L) was added trifluoroacetic acid TFA (5.4 g, 4.7 mmol). The reaction mixture was heated to 65-70 °C to 70 °C and compound 1-2 (414 g, 1.74mol) was added slowly maintaining reaction temperature 65- 70 °C. After completion of addition, the reaction mixture was heated at 65 °C to 70 °C for not less than 2 hours until completion of reaction as confirmed by UPLC (disappearance of compound 1-1). The reaction mixture was then cooled to -5 to 0 °C. Red-Al (1.6 Kg, 4.75 mol, 60-70% solution in toluene) was added slowly maintaining the temperature below -5 to 0 °C °C. The reaction mixture was then warmed to 25 °C to 30 °C and stirred for not less than 12 hours until completion of reaction as confirmed by UPLC (disappearance of compound 1-2). In another reactor-210% NaOH solution (4.0 L) was cooled to 0 °C. The reaction mixture was quenched by transferring into the cold 10% NaOH solution while maintaining the temperature below 30 °C. After completion of transfer, quench mixture allowed to stir for 3 hours and then layers allowed to separate. The organic layer was separated. The organic layer was, washed with water (2.0 L), 15% brine (2.0 L), and evaporated to dryness. The crude residue of compound 2 (424 g), a pale yellow oil was used as is in next step. Compound 2 (424 g, 1.7 mol) was taken in MeOH (1.7 L). Activated carbon (42.4 g, 0.10 w/w) added and heated to 40-45 °C for 2 h. The hot solution was filtered through hyflo bed and washed with MeOH (424 mL). Filtrate was transferred to hydrogenation autoclave flask, degassed and purged with N2, twice. 10 wt % Pd/C (50% wet, 42.4 g) was charged and the mixture was degassed and purged with H2, twice. The reaction mixture allowed to agitate under H2 atmosphere (100 psi) for not less than 20 hours until completion of reaction as confirmed by UPLC. The mixture was degassed and purged with N2, filtered through a pad of celite. The filtrate was evaporated to near dryness, co-distilled with Ethyl acetate (2 x 848 mL), triturated with Ethyl acetate (424 mL) at 25 to 30 °C for 3 h. Solids were filtered, washed with cold Ethyl acetate (212 mL) and dried in vacuum at <30 °C. Compound 3 (180.0 g, 71%) was obtained as off-white solid. m/z 160.11 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 4.18 (s, 2H), 3.34 (s, 2H), 3.25 (d, J = 10.5 Hz, 2H), 2.80 (d, J = 10.6 Hz, 2H), 2.44 (d, J = 10.5 Hz, 2H), 0.88 (d, J = 1.7 Hz, 6H). Example 2. Synthesis of Compound 4
Figure imgf000032_0001
To a solution of methyl sebacate (135.0 g, 848 mmol) in DCM (1350 mL), thionyl chloride (100.9 g, 848 mmol) and DMF (1.0 g) were sequentially charged with agitation while maintaining internal temperature 20 to 30 °C. The mixture allowed to agitate at 20 °C to 30 °C for not less than 2 hours until completion of reaction as confirmed by disappearance of methyl sebacate by UPLC. The mixture was evaporated to dryness and the residue co-distilled with DCM (675 mL) and then the acid chloride was made into a solution in DCM (675 mL). In another flask, a mixture of compound 3 in DCM (675 mL), water (1350 mL), K2CO3 (239.0 g, 2544 mmol) was cooled to 0 to 5 °C. To this cold mixture, acid chloride solution in DCM was added slowly dropwise with agitation in four portions with 15 min intervals, maintaining the temperature below 5 °C. The reaction mixture was then warmed to 25 °C to 30 °C and agitated for not less than 12 hours until completion of reaction as confirmed by UPLC. The mixture was diluted with Ethyl acetate (1500 mL), organic layer separated, washed with water (1350 mL), brine (675 mL), dried over Na2SO4 (135 g), evaporated and dried in vacuum at <45 °C. Compound 4 (260 g, 86%) was obtained as light-yellow colored liquid. m/z 358.18 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 4.66 (ddd, J = 13.8, 6.1, 3.8 Hz, 2H), 3.51 (dd, J = 10.2, 2.2 Hz, 1H), 3.41 – 3.32 (m, 1H), 3.31 (tt, J = 7.6, 3.8 Hz, 4H), 3.09 (dd, J = 10.3, 2.3 Hz, 1H), 2.99 (dd, J = 11.9, 2.4 Hz, 1H), 2.49 (d, J = 1.7 Hz, 1H), 2.27 (td, J = 7.4, 2.4 Hz, 2H), 2.14 (t, J = 7.6 Hz, 2H), 1.55 – 1.40 (m, 4H), 1.26 – 1.21 (m, 8H), 1.01 – 0.90 (m, 6H). Example 3. Synthesis of Compound 5
Figure imgf000033_0001
To a solution of compound 4 (35.0 g, 9.8 mmol) in DCM (350 mL), trimethylamine TEA (14.87 g, 14.7 mmol) and DMAP (1.2 g, 1.0 mmol) were added at 20 °C to 30 °C. This mixture was cooled to 0 °C to 5 °C and DMTrCl (33.2 g, 9.8 mmol) was added. The reaction mixture allowed to stir at the same temperature for not less than 2 hours until completion of reaction as confirmed by UPLC. Water (350 mL) was added and mixture allowed to warm to 20 to 30 °C and stirred for 30 minutes. The aqueous layer was separated and extracted with DCM (70 mL). The organic layers were pooled and washed with aqueous NaHCO3 solution (350 mL), brine (350 mL), dried over Na2SO4 (35.0 g), filtered and evaporated to dryness. The crude residue was purified by silica gel column chromatography (15 to 60% EA/hexanes) to give pure compound 5 (35.0 g, 54.1 %) as pale-yellow oil. m/z 660.58 [M+H]+. 1H NMR (400 MHz, Chloroform-d) δ 7.40 (d, J = 8.1 Hz, 2H), 7.34 – 7.17 (m, 9H), 6.83 (dd, J = 8.8, 2.6 Hz, 4H), 3.80 (s, 6H), 3.67 (s, 3H), 3.56 (d, J = 12.3 Hz, 1H), 3.49 – 3.18 (m, 3H), 3.12 (d, J = 9.9 Hz, 1H), 3.04 (s, 1H), 2.29 (td, J = 7.7, 3.8 Hz, 2H), 2.17 (q, J = 6.2, 4.8 Hz, 2H), 2.08 – 2.02 (m, 1H), 1.30 (s, 12H), 1.18 (d, J = 23.3 Hz, 3H), 1.03 (d, J = 4.8 Hz, 3H). Example 4. Synthesis of Compound 6
Figure imgf000033_0002
A solution of compound 5 (35.0 g, 5.3 mmol) in MeOH/Water (1:1, 700 mL) was cooled to 0 °C. LiOH.H2O (4.86 g, 11.6 mmol) was added and mixture stirred for not less than 1 hour until completion of reaction as confirmed by UPLC. Methanol was evaporated, water added and the mixture cooled to 0 to 5 °C. The mixture was neutralized to ~pH 7.0 with sodium dihydrogen phosphate solution and then acidified to pH 6 to 6.5 using acetic acid while maintaining the temperature below 5 °C. The aqueous mixture was extracted with DCM (2 x 350 mL) and evaporated to complete dryness and then further dried in a vacuum oven at 45 °C. Compound 6 (28.3 g, 82%) was obtained as off-white solid. m/z 646.54 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 11.96 (s, 1H), 7.32 (p, J = 7.6 Hz, 4H), 7.21 (t, J = 7.6 Hz, 5H), 6.87 (d, J = 8.2 Hz, 4H), 4.60 – 4.48 (m, 1H), 3.72 (s, 6H), 3.46 (dd, J = 30.2, 11.0 Hz, 1H), 3.20 (dd, J = 25.3, 11.0 Hz, 1H), 3.13 – 2.83 (m, 5H), 2.12 (dq, J = 31.7, 7.6 Hz, 4H), 1.49 – 1.41 (m, 4H), 1.22 (d, J = 10.2 Hz, 10H), 1.11 – 0.99 (m, 4H). Scheme 2
Figure imgf000034_0001
Example 5. Synthesis of Compound 9
Figure imgf000034_0002
19.0 g (1.0 equiv) of Compound 8 after azeotrope concentration with toluene to remove any water content) and 190 mL (10 V) of DCM were charged to a 500 mL of reactor. After cooling to -20 °C, 20.6 g (0.95 equiv) of Cbz-Cl was slowly charged at -20 ~ -10 °C for 2 hours using a syringe pump. Then, 14.2 g (1.10 equiv) of TEA was slowly charged at -20 ~ -7 °C for 2 hours using a syringe pump. The reaction mixture was agitated at room temperature for 17 hours to complete the reaction conversion. The contents were washed with 95 mL (5 V) of 1N HCl, 95 mL (5 V) of 8wt% NaHCO3 and 95 mL (5 V) of brine in a sequence. Then, 38 mL (2 V) of purified water was added to the organic layer and the contents were concentrated under 20 torr at 65 °C with a water bath. The process for azeotrope concentration was repeated 2 times with water (distillation with water removes impurities). After azeotrope concentration, the concentrate was diluted with 57 mL (3 V) of DCM and treated with 19 g (1 S) of Na2SO4. The contents were filtered and the waste was washed with 38 mL (2 V) of DCM. The filtrates were concentrated under 20 torr at 65 °C with a water bath, and then it was dried under full vacuum at 50 °C for weekend to give the product compound 9 (185 g, 97% Yield) as a colorless oil. m/z 284.2 [M+H]+. 1H NMR (600 MHz, DMSO 7.28 (m, 3H), 7.32 – 7.22 (m, 2H), 5.73 (s, 1H), 5.00 (s, 3H), 4.56 (t, J = 5.5 Hz, 2H), 3.47 (t, J = 5.3 Hz, 4H), 3.40 (td, J = 5.6, 5.2, 2.2 Hz, 7H), 3.33 (s, 1H), 3.14 (q, J = 6.0 Hz, 4H) Example 6. Synthesis of Compound 10
Figure imgf000035_0002
To a solution of compound 9 (10 g, 35.3 mmol) in DCE (100 mL) was added compound 7 (16.5 g, 42.4 mmol) and TMSOTf (0.6 mL, 3.5 mmol). The mixture was agitated at 60 to 65 °C for not less than 3 hours until completion of reaction as confirmed by UPLC. The mixture was allowed to cool to 20 °C to 25 °C and sequentially washed with 8 wt% aq. NaHCO3 (2 x 60 mL), 1N HCl (120 mL), brine (120 mL), dried over Na2SO4 (120 g) and evaporated to dryness to give compound 10 (22.7 g, quantitative yield) as a light-yellow syrup. m/z 613.3 [M+H]+. 1H NMR (600 MHz, DMSO-d6) δ 7.78 (d, J = 9.2 Hz, 1H), 7.38 – 7.26 (m, 5H), 7.29 – 7.22 (m, 1H), 5.20 (d, J = 3.4 Hz, 1H), 5.01 – 4.93 (m, 3H), 4.54 (d, J = 8.5 Hz, 1H), 4.01 (m, 3H), 3.86 (m, 1H), 3.76 (m, 1H), 3.60 – 3.51 (m, 1H), 3.54 – 3.43 (m, 6H), 3.39 (t, J = 6.0 Hz, 2H), 3.13 (q, J = 6.0 Hz, 2H), 2.08 (s, 3H), 1.98 (s, 3H), 1.87 (s, 3H), 1.75 (s, 3H). Example 7. Synthesis of Compound 11
Figure imgf000035_0001
To a solution of compound 10 (110 g, 179 mmol) in THF (100 mL), TFA (20.5 g, 179 mmol) was added. The mixture was degassed and purged with N2, twice. 10 wt % Pd/C (11 g) was charged and the mixture was degassed and purged with H2, twice. The mixture was allowed to agitate under H2 atmosphere (70 psi) for not less than 3 hours until completion of reaction as confirmed by UPLC. The mixture was degassed and purged with N2, filtered through a pad of celite. The filtrate was evaporated to complete dryness to give compound 11 (106 g, quantitative yield) as a light-yellow foamy solid. m/z 479.2 [M+H]+. 1H NMR (600 MHz, DMSO-d6) δ 7.93 (dd, J = 12.4, 5.3 Hz, 4H), 5.20 (d, J = 3.4 Hz, 1H), 4.96 (dd, J = 11.2, 3.4 Hz, 1H), 4.54 (d, J = 8.5 Hz, 1H), 4.06 – 3.96 (m, 3H), 3.88 (dt, J = 11.1, 8.8 Hz, 1H), 3.78 (m, 1H), 3.58 (t, J = 5.2 Hz, 3H), 3.58 – 3.45 (m, 6H), 2.96 (h, J = 5.6 Hz, 2H), 2.08 (s, 3H), 1.98 (s, 3H), 1.87 (s, 3H), 1.76 (s, 3H). Scheme 3
Figure imgf000036_0001
Example 8. Synthesis of Compound 15C
Figure imgf000036_0002
A solution of DMF (1000 mL) and DIPEA (275.3 g, 2.13 mmol) was cooled to 0 to 5 °C. Sequentially charged compound 15-A (100 g, 0.35 mol), EDC.HCl (217.1 g, 1.13 mol) and HOBt monohydrate (173.9 g, 1.13 mol) while maintaining temperature 0 to 5 °C. Agitated for 10 min and then compound 15-B (163.4 g, 1.17 mol) was charged. The reaction mixture was allowed to warm to 25 °C to 30 °C and stirred for not less than 16 hours until completion of reaction as confirmed by UPLC. The reaction mixture was diluted by slow addition of Ethanol (1000 mL) followed by water (4500 mL) and allowed to stir for not less than 4 h at 25 °C to 30 °C. A precipitate formed which was filtered, washed with water (1000 mL) and solids dried in vacuum at <50 °C. Compound 15C (134.0 g, 83% Yield) was obtained as a white solid. m/z 452.21 [M+H]+. Example 9. Synthesis of Compound 15D
Figure imgf000036_0003
To a solution of compound 15C (50 g, 11.1 mmol) in MeOH/Water (1:1, 500 mL), a solution of NaOH (9.8 g, 24.4 mmol) in water (250 mL) was added slowly at 25 °C to 35 °C. The reaction mixture was allowed to stir for not less than 6 hours until completion of reaction as confirmed by UPLC. MeOH was evaporated. The aqueous solution was rendered acidic to pH~1-2 by addition of 6.0 N HCl solution and saturated with NaCl. The aqueous layer was extracted with ethyl acetate (3 x 750 mL). Th h l ate layers were pooled, dried over Na- SO4 (100 g) and evaporated to dryness. The crude residue was triturated with hexanes (250 mL), filtered, washed with hexanes (100 mL) and dried under vacuum at 45 °C. Compound 15D (20.0 g, 49%) was obtained as a white solid. m/z 396.11 [M+H]+. Scheme 4
Figure imgf000037_0001
Example 10. Synthesis of Compound 13A
Figure imgf000037_0002
A solution of compound 15C (80.0 g, 0.17 mol) in THF(2800 mL) was degassed and purged with N2, twice. 10 wt % Pd/C (50% wet, 8.0 g) was charged and the mixture was degassed and purged with H2, twice. The mixture was allowed to agitate under H2 atmosphere (100 psi) for not less than 6 hours until completion of reaction as confirmed by UPLC. The mixture was degassed and purged with N2, filtered through a pad of celite. The filtrate was evaporated, solvent swaped with Ethyl acetate (2 x 400 mL). Residue taken in Ethyl acetae (400 mL) at 45 °C and n-Heptane (320 mL) slowly added, stirred at 45 °C for 1 h and then at 0 to 5 °C for 1 h. Solids were filtered, washed with cold solution of Ethyl acetate/n-Heptane (1:2, 160 mL) and dried in vacuum oven 25 to 30 °C to give compound 13A (46.2 g, 82% yield) as white solid. m/z 318.14 [M+H]+. Example 11. Synthesis of Compound 13B A solution of DCM and DIPEA (5.9 g, 46.4 mmol) was cooled to 0 to 5 °C. Sequentially charged compound 6 (15.0 g, 23.2 mmol), EDC.HCl (5.1 g, 26.7 mmol), HOBt monohydrate (4.1 g, 26.7 mmol) while maintaining 0 to 5 °C. Mixure was stirred for 10 min, compound 13A (7.74 g, 24.3 mmol) was charged and allowed to stir at 0 to 5 °C for NLT 21 h until completion of reaction as confirmed by UPLC. Charged purified water (150 mL) while maintaining below 30 °C. Organic layer separated, washed with aq. NaHCO3 (2 x 105 mL) and 10% aq. NaCl. Organic layer evaporated, solvent swapped with Ethyl acetate twice (300 ml and 150 mL). When at 4V total volume, n-Heptane added and heated 50 to 55 °C for 1 h and then cooled at 0 to 5 °C for 1 h. Solids filtered, washed with mother liquor, n-Heptane (30 mL) an dried solids in vacuum at 40 to 45 °C. Compound 13B (17.9 g, 81%) was obtained as white solid. . m/z 946.05 [M+H]+. Example 12. Synthesis of Compound 13C
Figure imgf000038_0001
A solution of compound 13B (10.0 g, 10.6 mmol) in THF (100 mL) was cooled to 0 to 5 °C. KOH solution (1.5 g, 26.4 mmol in 50 mL water) was added at below 5 °C. The reaction mixture was warmed to 25 to 30 °C and stirred for not less than 4 hours until completion of reaction as confirmed by UPLC. Mixture cooled to 0 to 5 °C, adjusted pH to ~7.0 with aqs. Sodium dihydrogen phosphate solution while maintaining temperature below 10 °C. Charged 2- methyltetrahydrofuran (150 mL). Adjusted pH to 4-5 by using 1N HCl while maintaining temperature below 10 °C. Allowed the mixture to stir at 25 to 30 °C for 20 min. Seperated organic layer, back washed aqueous layer with 2-methyltetrahydrafuran. Organic layers pooled and washed with 10% aqs NaCl (50 mL). To organic layer triethylamine (4.3 g, 42.4 mmol) was added, allowed to stir for 1 h and then evaporated, solvent swapped with tetrahydrofuran (20 mL) and then evaporated to complete dryness and further dried in vacuum oven. compound 13C (TEA salt) (9.0 g, 84%) was obtained as a white hygroscopic solid. m/z 889.13 [M+H]+. Scheme 5 y
Figure imgf000039_0001
Example 13. Synthesis of Compound 12
Figure imgf000040_0001
To a solution of compound 16-1 (41.5 g, 196.6 mmol) in DCM (415 mL), N- Hydroxysuccicnimide (49.7 g, 432.4 mmol) and EDC.HCl (82.9 g, 432.4 mmol) were added. The reaction mixture was allowed to stir at 25 °C to 30 °C for not less than 16 hours until completion of reaction to form compound 11B as confirmed by TLC. Reaction mixture was evaporated to 2-3V, water (415 mL) was added and allowed to stir the solids at 25 to 30 °C for 1 h. Filtered the solids, washed with water (415 mL) and wet solids triturated with aqs. NaHCO3 solution (415 mL) at 25 to 30 °C for 1 h. Solids were filtered again, washed with water (415 mL), MTBE (210 mL) and dried in vacuum below 45 °C to give compound 11B as a white solid (45.0 g, 56% yield). A solution of compound 11 (110.0 g, 185.64 mmol) in DCM (1100 mL) was cooled to 0 to 5 °C. Compound 11B (33.85 g, 83.54 mmol) and DIPEA (47.9 g, 371.3 mmol) were charged at below 10 °C and allowed to stir at 20 °C to 25 °C for no less than 3 hours until completion of reaction as confirmed by UPLC. Water (1100 mL) was added to the mixture at below 30 °C and stirred for 45 min. Organic layer was separated, washed with aqs. NaHCO3 solution (1100 mL), 1N HC1 (1100 mL) and15% aqs. NaCl (1100 mL). Organic layer evaporated and solvent swapped with MTBE (500 mL) and taken into MTBE (500 mL), stirred for 3 h at 25 to 30 °C. Resulting solids were filtered, washed with MTBE (250 mL) and and dried in vacuum at <50 °C. Compound 12 (90.0 g, 86% Yield) was obtained as a light-yellow foam solid. m/z 1132.5 [M+H]+. Example 14. Synthesis of Compound 13
Figure imgf000041_0001
A solution of compound 12 (39 g, 34.45 mmol) in THF (240 mL) was degassed and purged with N2, twice. 10 wt % Pd/C (3.9 g) was charged and the mixture was degassed and purged with H2, twice. The reaction mixture allowed to agitate under H2 atmosphere for not less than 4 hours until completion of reaction as confirmed by UPLC. The mixture was degassed and purged with N2, filtered through a pad of celite (39 g). The filtrate was evaporated to complete dryness to give compound 13 (36.4 g, 95% yield) as a grey foam solid. m/z 1102.5 [M+H]+. Example 15. Synthesis of Compound 14
Figure imgf000041_0002
A solution of compound 13 (30 g, 22.72 mmol) and N-carbobenzoxyglycine (7.97g, 38.11 mmol), in DCM (150 mL) was cooled to 0 to 5 °C, the following were charged sequentially with agitation at below 5 °C, TEA (7.6 mL, 54.44 mmol), and T3P (29.2 mL, 49 mmol, 50% solution in ethyl acetate). The reaction mixture was agitated at 0 °C to 5 °C for not less than 3 hours until completion of reaction as confirmed by UPLC. Reaction mixture was washed sequentially with water (110 mL), saturated aq. NaHCO3 (110 mL), brine (110 mL), then dried over Na2SO4 (60 g) and evaporated to complete dryness to give compound 14 (32 g, 91% yield) as a grey foam solid. m/z 1293.6 [M+H]+. Example 16. Synthesis of Compound 15
Figure imgf000042_0001
A solution of compound 14 (68 g, 52.78 mmol) in THF (400 mL) was degassed and purged with N2, twice. 10 wt % Pd/C (6.8 g) and TFA (4.4 mL, 57.84 mmol) were charged and the mixture was degassed and purged with H2, twice. The reaction mixture allowed to agitate under H2 atmosphere for not less than 4 hours until completion of reaction as confirmed by UPLC. The mixture was degassed and purged with N2, filtered through a pad of celite (68 g). The filtrate was evaporated to complete dryness to give compound 15 (63 g, 95% yield) as a grey foam solid. m/z 1159.6 [M+H]+ (Free base). Scheme 6
Figure imgf000042_0002
Figure imgf000043_0001
Example 17. Synthesis of Compound 16-2
Figure imgf000043_0002
To a suspension of compound 16-1 (50 g, 236 mmol) in DCM (500 mL), oxalyl chloride (69 g, 543 mmol) and DMF (172 mg, 2.3 mmol) were sequentially charged with agitation while maintaining internal temperature 20 to 30 °C. The mixture was allowed to agitate 20°C to 30 °C for not less than 12 hours until completion of reaction as confirmed by disappearance of compound 16-1 by UPLC. The mixture is evaporated to dryness and the residue is taken into toluene. To the toluene solution were charged t-BuOH (52.5 g, 708mmol) and DMAP (66.3 g, 543 mmol). This mixture was allowed to agitate for not less than 4 hours at 20 °C to 25 °C until completion of reaction as confirmed by UPLC. The mixture was filtered, filtrate washed with 5 % aqueous citric acid solution (500 mL), brine (500 mL), dried over NaSO4 (100 g) and evaporated. The residue was azeotroped with n-hexane (250 mL), evaporated and dried to give compound 16-2 (73 g, 95% Yield) as off-white solid. m/z 341.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d) δ 8.92 (s, 2H), 8.87 (s, 1H), 1.64 (s, 18H). Example 18. Synthesis of Compound 16-3
Figure imgf000043_0003
A solution of compound 16-2 (30 g, 923 mmol) in MeOH (360 mL) was degassed and purged with N2, twice. 10 wt % Pd/C (3 g) was charged and the mixture was degassed and purged with H2, twice. The mixture was allowed to agitate under H2 atmosphere for not less than 6 hours until completion of reaction as confirmed by UPLC. The mixture was degassed and purged with N2, filtered through a pad of celite. The filtrate was evaporated to complete dryness to give compound 16-3 (26 g, 95% yield) as off-white solid. m/z 294.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d) δ 7.96 (d, J = 1.7 Hz, 1H), 7.45 (d, J = 1.5 Hz, 2H), 3.92 (s, 2H), 1.59 (s, 18H). Example 19. Synthesis of Compound 16-4
Figure imgf000044_0001
To a solution of compound 16-3 (23.7 g, 80.7 mmol) in DCM (355 mL), the following were charged sequentially with agitation at 15 to 25 °C, N-carbobenzoxyglycine (23.7g, 113 mmol), TEA (16.3 g, 161 mmol), T3P (92.3 g, 145 mmol, 50% solution in ethyl acetate). The mixture was agitated at 15 °C to 25 °C for not less than 2 hours until completion of reaction as confirmed by UPLC. The mixture was washed sequentially with water (240 mL), saturated aq.NaHCO3 (240 mL), brine (240 mL), then dried over Na2SO4 (48 g) and evaporated to complete dryness to give compound 16-4 (46.2 g, 118% yield) as a pale yellow solid. m/z 484.2 [M+H]+. 1H NMR (400 MHz, Chloroform-d) δ 8.95 (s, 1H), 8.34 (s, 2H), 8.29 (s, 1H), 7.36 – 7.27 (m, 5H), 5.99 (s, 1H), 5.16 (s, 2H), 4.12 (d, J = 5.6 Hz, 2H), 1.57 (s, 18H). Example 20. Synthesis of Compound 16-5
Figure imgf000044_0002
A solution of compound 16-4 (46.2 g, 95.3 mmol) in MeOH (1150 mL) was degassed and purged with N2, twice. 10 wt % Pd/C (4.6 g) was charged and the mixture was degassed and purged with H2, twice. The mixture was allowed to agitate under H2 atmosphere for not less than 3 hours until completion of reaction as confirmed by UPLC. The mixture was degassed and purged with N2, filtered through a pad of celite The filtrate was evaporated, residue taken in methylene chloride (500 mL), evaporated to complete dryness to give compound 16-5 (32.4 g, 97% yield) as pale yellow solid. m/z 351.2 [M+H]+. 1H NMR (600 MHz, Chloroform-d) δ 9.63 (s, 1H), 8.37 (d, J = 1.6 Hz, 2H), 8.31 (t, J = 1.5 Hz, 1H), 3.49 (d, J = 18.7 Hz, 4H), 1.59 (s, 18H). Example 21. Synthesis of Compound 16D
Figure imgf000045_0001
To a solution of compound 16-5 (32.5g, 92.7 mmol) in methylene chloride (455 mL), compound 15A (11.7 g, 41.7 mmol) and HBTU (52.7 g, 139 mmol) were added. To this mixture TEA (28.1 g, 278 mmol) was added while maintaining internal temperature at 15 °C to 25 °C. Reaction mixture allowed to stir at the same temperature for not less than 6 hours until completion of reaction as confirmed by UPLC. Reaction mixture was sequentially washed with water (320 mL), aqs. NaHCO3 (320 mL), brine (320 mL), dried over Na2SO4 and evaporated to dryness. The crude residue was purified by column chromatography (30% to 100% EA/Hexanes) to give compound 16D (45.2 g, 51% Yield) as a white solid. m/z 946.5 [M+H]+. 1H NMR (600 MHz, DMSO-d6) δ 8.39 (d, J = 15.5 Hz, 5H), 8.22 (t, J = 5.7 Hz, 1H), 8.05 (s, 2H), 7.35 – 7.24 (m, 5H), 5.06 (t, J = 9.3 Hz, 2H), 4.05 (q, J = 7.1 Hz, 1H), 3.98 – 3.87 (m, 4H), 2.28 (hept, J = 7.9, 7.1 Hz, 2H), 1.96 (dt, J = 18.0, 6.7 Hz, 1H), 1.82 (dd, J = 14.5, 7.2 Hz, 1H), 1.53 (d, J = 3.5 Hz, 36H). Example 22. Synthesis of Compound 16E
Figure imgf000046_0001
To a solution of compound 16D (30.0 g, 31.7 mmol) in methylene chloride (600 mL), TFA (108.4 g, 951 mmol) was added while maintaining internal temperature at 15 °C to 25 °C. Reaction mixture was allowed to stir at 20 °C to 25 °C for not less than 12 hours until completion of reaction as confirmed by 1H NMR. Mixture was evaporated to dryness, residue taken in methylene chloride (300 mL) and evaporated again to dryness. The resulting residue was partitioned between methylene chloride (300 mL) and 8 wt% aqs. NaHCO3 solution (600 mL). Organic layer separated, aqueous layer washed again with methylene chloride (300 mL). Methylene chloride layers discarded. Aqueous layer acidified with 3N HCl (~600 mL) to adjust to pH 3-4. The solids formed were filtered, washed with water and dried at 45 °C for not less than 12 hours to give compound 16E (16.4 g, 95% yield) as a white solid. m/z 722.2 [M+H]+. 1H NMR (600 MHz, DMSO-d6) δ 10.31 (s, 1H), 10.11 (s, 1H), 8.48 – 8.38 (m, 5H), 8.30 (s, 0H), 8.25 (t, J = 5.8 Hz, 1H), 8.15 (dt, J = 3.4, 1.6 Hz, 2H), 7.67 (d, J = 6.9 Hz, 1H), 7.37 – 7.24 (m, 5H), 5.12 – 5.01 (m, 2H), 4.03 (q, J = 7.1 Hz, 1H), 3.91 (dd, J = 21.2, 6.1 Hz, 4H), 2.49 (s, 0H), 2.35 – 2.22 (m, 2H), 1.95 (ddt, J = 15.0, 9.0, 5.9 Hz, 1H), 1.87 – 1.79 (m, 1H). Example 23. Synthesis of Compound 16
Figure imgf000046_0002
To a solution of compound 15 (40 g, 31.82 mmol) in DMF (400 mL), compound 15A (4.0 g, 14.32 mmol) and HBTU (14.5 g, 38.18 mmol) were added. The reaction mixture was cooled to 10 °C to 15 °C TEA (10.6 mL, 76.36 mmol) was added while maintaining internal temperature at 10 °C to 15 °C. The reaction mixture allowed to warm to 20 °C to 25 °C and stir for not less than 3 hours until completion of reaction as confirmed by UPLC. He reaction mixture was quenched by addition of water (400 mL) and Ethyl acetate (400 mL). The aqueous layer was separated and extracted with DCM (3 x 400 mL). The DCM layers were pooled, washed with water (5 x 200 mL), dried over Na2SO4, filtered and evaporated to complete dryness. Compound 16 (31.7 g, 87% yield) was obtained as light-yellow foam solid. m/z 2563.9 [M+H]+ Example 24. Synthesis of Compound 16
Figure imgf000047_0001
To a solution of compound 11 (1.0 g, 1.74 mmol) in anhydrous DMF (9 mL), compound 16E (0.21g, 0.29 mmol)), EDC (333 mg, 1.74 mmol), HOBt (265 mg, 1.74 mmol) were sequentially added and the mixture cooled to 0 °C to 5 °C. DIPEA (450 mg, 3.48 mmol) was added maintaining the internal temperature at 0 °C to 5 °C and allowed to stir at the same temperature for not less than 24 hours until completion of reaction as confirmed by UPLC. Reaction mixture diluted with water (11 mL), extracted with methylene chloride (50 mL). The methylene chloride layer was washed with water (2 x 5 mL), dried over Na2SO4 and evaporated to dryness. The residue was purified by column (2 to 15% MeOH/DCM) to give pure compound 16 (360 mg, 49.5% yield) as foamy solid. Example 25. Synthesis of Compound 16
Figure imgf000048_0001
A solution of compound 15D (1.6 g, 4.08 mmol) and compound 13 (10 g, 9.07 mmol) in DCM (100 mL) was cooled to 0 °C to 10 °C. TEA (1.84 g, 18.14 mmol) and T3P (10.34 mL, 16.3 mmol, 50% solution in ethyl acetate) were charged sequentially with agitation at 0-10 °C. The reaction mixture was agitated at 25 °C to 35 °C for not less than 6 hours until completion of reaction as confirmed by UPLC. The reaction was quenched by addition of water (200 mL). The aqueous layer was separated and extracted with DCM (50 mL). The DCM layers were pooled and washed sequentially with saturated aq.NaHCO3 (200 mL), 1.0 N HCl (200 mL), 10% aq. NaCl solution (200 mL), then dried over Na2SO4 (25 g) and evaporated to about 20 g. MTBE (50 mL) was added and evaporated to complete dryness and further dried in vacuum at 45 °C. Compound 16 (10.3 g, 89% yield) was obtained as a pale yellow solid. Example 26. Synthesis of Compound 17
Figure imgf000048_0002
A solution of compound 16 (2.7 g, 1.05 mmol) in MeOH (27 mL) was degassed and purged with N2, twice. 10 wt % Pd/C (0.27 g) and TFA (156 mg, 1.37 mmol) were charged and mixture was purged with H2. The reaction mixture was allowed to agitate under H2 atmosphere for not less than 3 hours until completion of reaction as confirmed by UPLC. The mixture was degassed and purged with N2, filtered through a pad of celite. The filtrate was evaporated, residue taken in methylene chloride (25 mL), evaporated to complete dryness to give compound 17 (2.4 g, 90% yield) as grey foamy solid. m/z 2428.9 [M+H]+. 1H NMR (600 MHz, DMSO- d6) δ 8.54 (q, J = 5.2 Hz, 1H), 8.21 (d, J = 5.3 Hz, 1H), 8.14 (t, J = 1.8 Hz, 1H), 7.95 (d, J = 8.7 Hz, 1H), 7.80 (d, J = 9.2 Hz, 1H), 5.19 (d, J = 3.4 Hz, 1H), 4.95 (dd, J = 11.2, 3.4 Hz, 1H), 4.52 (d, J = 8.5 Hz, 1H), 4.07 – 3.97 (m, 3H), 3.94 – 3.82 (m, 2H), 3.76 (m, 1H), 3.59 – 3.47 (m, 8H), 3.44 (m, 3H), 2.38 (t, J = 7.8 Hz, 1H), 2.08 (s, 3H), 1.98 (s, 3H), 1.87 (s, 3H), 1.75 (s, 3H). Example 27. Synthesis of Compound 18
Figure imgf000049_0001
To a solution of compound 17 (1.0 g, 0.39 mmol) in DCM (25 mL), compound 6 (0.29g, 0.44 mmol), HBTU (186 mg, 0.49 mmol), were added and mixture cooled to 15 °C to 25 °C. DIPEA (151 mg, 1.17 mmol) was added maintaining the internal temperature at 15 °C to 25 °C and then allowed to stir at 20 °C to 25 °C for not less than 2.5 hours until completion of reaction as confirmed by UPLC. The reaction mixture diluted with DCM (5 mL) washed with water (10 mL), aq. NaHCO3 solution (3 x 8 mL), brine (10 mL), dried over Na2SO4 and evaporated to dryness. The residue was purified by column (2 to 18% MeOH/DCM) to give pure compound 18 (860 mg, 72.5% yield) as off-white foamy solid. m/z (z=2) 1378.5 [M- DMTr+2H]2+. Example 28. Synthesis of Compound 18
Figure imgf000050_0001
A solution of compound 13C (39.8 g, 40.2 mmol) and compound 13 (93 g, 84.39 mmol) in THF (800 mL) was cooled to 0 to 10 °C. TEA (0.5 mL, 3.6 mmol) and T3P (20.3 g, 200.9 mmol, 50% solution in ethyl acetate) were charged sequentially with agitation at 0-10 °C. The reaction mixture was agitated at 25 to 35 °C for not less than 18 hours until completion of reaction as confirmed by UPLC. The reaction mixture was quenched by addition of saturated aq.NaHCO3 (800 mL) (10 mL) and 2-MeTHF (800 mL). The aqueous layer was separated. The organic layer was washed sequentially with 5% NaH2PO4 (800 mL), 10% aq. NaCl solution (800 mL), then dried over Na2SO4 and evaporated. Solvent swapped to MTBE (400 mL), allowed to stir for 3-4 h and evaporated to complete dryness and further dried in vacuum at 45 °C. Crude compound 18 (120 g) was obtained as a solid. Crude material is purified by column chromatography to ≥97% purity and taken to next step. m/z (z=2) 1378.5 [M-DMTr+2H]2+. Example 29. Synthesis of Compound 19
Figure imgf000051_0001
To a solution of compound 18 (1.1 Kg, 163.6 mmol) in DCM (1.1 L), TEA (126 g, 1260 mmol) was charged slowly charged keeping the temperature at 25 °C. Compound 18A (126 g, 1260 mmol) was then charged in portions maintaining the temperature at 25 °C. The resulting mixture was agitated at 40 to 45 °C for not less than 72 hours until completion of reaction as confirmed by UPLC. The reaction mixture was cooled to 20 °C to 25 °C and washed with aq. NaHCO3 solution (2 x 5L), dried over Na2SO4, filtered and evaporated to complete dryness. Compound 19 was obtained as off-white solid (1.0 Kg). For free acid: m/z (z=2) 1428.5 [M- DMTr+2H]2+. Example 30. Synthesis of The Crystalline Potassium Salt Of The Compound Of Formula 13CC:
Figure imgf000052_0001
5.0 g (1.0 equiv) of Compound 13BB, and 25 mL (5 V) of MeOH were charged to a reactor (100 mL). After dissolution, the contents were adjusted to 0-5 °C.653 mg (2.2 equiv) of KOH was dissolved with 25 mL (5 V) of MeOH in another reactor. KOH in MeOH was slowly charged to the contents, and the reaction mixture was slowly adjusted to 40 °C. The reaction mixture was agitated until the reaction was complete. After concentration to minimum volume, 10 V of CPME was charged and the contents were agitated at 50-60 °C. During the agitation, a pale yellow slurry formed. The slurry was concentrated to minimum volume under reduced pressure. After charging 10 V of heptane, the slurry was agitated at 50-60 °C for 1 hour and slowly adjusted to 0-5 °C. After agitation for 1 hour, the contents were filtered via filter paper and the wet cake was washed with 2 V of heptane. 5.2 g of product was obtained as a off-white solid. All publications, patents, and patent documents are incorporated by reference herein, as though individually incorporated by reference. The invention has been described with reference to various specific and preferred embodiments and techniques. However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the invention.

Claims

CLAIMS 1. A method for preparing a compound of formula 1:
Figure imgf000053_0001
comprising reacting a compound of formula 1-1:
Figure imgf000053_0002
with a compound of formula 1-2:
Figure imgf000053_0003
at a temperature of 40 °C or greater. 2. The method of claim 1 wherein the compound of formula 1-1 is reacted with the compound of formula 1-2 in a solvent that comprises tetrahydrofuran. 3. The method of claim 1 or 2 wherein the compound of formula 1-1 is reacted with the compound of formula 1-2 in a solvent that comprises tetrahydrofuran at a temperature of 60 °C or greater. 4. A method for preparing a crystalline form of compound 3:
Figure imgf000053_0004
comprising converting a compound of formula 1:
Figure imgf000054_0001
to the crystalline form of compound 3 without using column chromatography during the conversion. 5. A crystalline form of compound 3:
Figure imgf000054_0002
. 6. A method for preparing a compound of formula 9:
Figure imgf000054_0003
wherein R9 is an optionally substituted benzyloxycarbonyl group, comprising converting a compound of formula 8:
Figure imgf000054_0004
or a salt thereof to the compound of formula 9. 7. The method of claim 6 wherein R9 is benzyloxycarbonyl or nitrobenzyloxycarbonyl. 8. The method of claim 6 wherein the compound of formula 8 is converted to the compound of formula 9 by treating the compound of formula 8 with benzyloxycarbonyl chloride in a suitable solvent in the presence of a suitable base.
9. A method for preparing a compound of formula 10:
Figure imgf000055_0001
wherein R9 is an optionally substituted benzyloxycarbonyl group, comprising converting a corresponding compound of formula 9:
Figure imgf000055_0002
to the compound of formula 10. 10. The method of claim 9 wherein the compound of formula 9 is converted to the compound of formula 10 by treatment with a compound of formula 7:
Figure imgf000055_0003
in the presence of a suitable catalyst and a suitable solvent. 11. The method of claim 10 wherein the catalyst is Sc(OTf)3 and wherein the suitable solvent comprises dichloroethane. 12. A method for preparing a compound of formula 10:
Figure imgf000055_0004
wherein R9 is an optionally substituted benzyloxycarbonyl group, comprising converting a compound of formula 8:
Figure imgf000055_0005
or a salt thereof to a corresponding compound of formula 9;
Figure imgf000056_0001
and subsequently converting the corresponding compound of formula 9 to the compound of formula 10, without purifying the compound of formula 9 by chromatography. 13. A method for preparing a salt of formula 11:
Figure imgf000056_0005
comprising treating a compound of formula 10:
Figure imgf000056_0002
wherein R9 is an optionally substituted benzyloxycarbonyl group, with hydrogen and trifluoroacetic acid in the presence of a suitable catalyst and in the presence of a suitable solvent. 14. The method of claim 13 wherein the suitable catalyst comprises palladium on carbon and wherein the suitable solvent comprises tetrahydrofuran. 15. A method for preparing a compound of formula 15D:
Figure imgf000056_0003
or a salt thereof, comprising converting a compound of formula 15C:
Figure imgf000056_0004
wherein each R15 is a (C1-C6)alkyl, to the compound of formula 15D or the salt thereof.
16. A method for preparing a compound of formula 15C:
Figure imgf000057_0005
wherein each R15 is a (C1-C6)alkyl, comprising reacting a compound of formula 15A:
Figure imgf000057_0001
or a salt thereof, with a corresponding compound of formula 15B:
Figure imgf000057_0002
or a salt thereof, to provide the compound of formula 15C. 17. A method for preparing a compound of formula 13A:
Figure imgf000057_0003
wherein each R15 is a (C1-C6)alkyl, comprising converting a corresponding compound of formula 15C:
Figure imgf000057_0004
wherein each R15 is a (C1-C6)alkyl, to the compound of formula 13A.
18. A method for preparing a compound of formula 13B:
Figure imgf000058_0003
wherein each R15 is a (C1-C6)alkyl and T is an optionally substituted triphenylmethyl group, comprising converting a corresponding compound of formula 13A:
Figure imgf000058_0001
to the compound of formula 13B. 19. The method of claim 18 wherein the compound of formula 13A is converted to the compound of formula 13B, by treating the compound of formula 13A with a corresponding compound of formula 6:
Figure imgf000058_0004
or a salt thereof, under suitable amide forming conditions. 20. A method for preparing a compound of formula 13CC:
Figure imgf000058_0002
comprising converting a compound of formula 13BB:
Figure imgf000059_0001
wherein each R15 is a (C1-C6)alkyl, to the compound of formula 13CC. 21. The method of claim 20 wherein the compound of formula 13BB is converted to the compound of formula 13CC by treatment with lithium hydroxide in a suitable solvent. 22. A method for preparing a potassium salt of a compound of formula 13CC:
Figure imgf000059_0002
comprising treating a compound of formula 13CC or a salt thereof with potassium carbonate in a suitable solvent to provide the potassium salt of the compound of formula 13CC. 23. A method for preparing a compound of formula 11B:
Figure imgf000059_0003
comprising converting a compound of formula 11A:
Figure imgf000059_0004
or a salt thereof, to the compound of formula 11B.
24. The method of claim 23 wherein the compound of formula 11A is converted to the compound of formula 11B by treating the compound of formula 11A or the salt thereof with 1- ethyl-3-(3-dimethylaminopropyl)carbodiimide in a suitable solvent. 25. A method for preparing a compound of formula 12:
Figure imgf000060_0001
comprising converting a compound of formula 11B:
Figure imgf000060_0002
to the compound of formula 12. 26. The method of claim 25, wherein the compound of formula 11B is converted to the compound of formula 12 by treating the compound of formula 11B with a compound of formula 11:
Figure imgf000060_0003
or a salt thereof, in the presence of a suitable base and a suitable solvent.
27. A method for preparing a compound of formula 13:
Figure imgf000061_0001
or a salt thereof, comprising reducing a compound of formula 12:
Figure imgf000061_0002
to provide the compound of formula 13 or the salt thereof. 28. The method of claim 27, wherein the compound of formula 13 or a salt thereof, is a trifluoroacetic acid salt of the following formula:
Figure imgf000061_0003
29. A method for preparing a compound of formula 14: comprising converting a compound of formula 13:
Figure imgf000062_0001
or a salt thereof to the compound of formula 14. 30. The method of claim 29, wherein the compound of formula 13 is converted to the compound of formula 14, by treating the compound of formula 13 with a compound of formula:
Figure imgf000062_0002
or a salt thereof, under suitable coupling conditions. 31. A method for preparing a compound of formula 16:
Figure imgf000062_0003
wherein R16 is an amine protecting group, comprising converting a compound of formula 13:
Figure imgf000063_0001
or a salt thereof, to the compound of formula 16. 32. The method of claim 31, wherein the compound of formula 13 or the salt thereof is converted to the compound of formula 16, by treating the compound of formula 13 with a compound of formula 15DD:
Figure imgf000063_0002
wherein R16 is an amine protecting group, or a salt thereof, under suitable coupling conditions. 33. The method of claim 31, wherein a trifluoroacetic acid salt of a compound of formula 13:
Figure imgf000063_0003
is treated with a compound of formula 15D:
Figure imgf000063_0004
under suitable coupling conditions to provide a compound of formula 16:
Figure imgf000064_0001
wherein R16 is benzyloxycarbonyl. 34. The method of any one of claims 31-33, wherein the compound of formula 13 is treated with the compound of formula 15D or 15DD in the presence of propanephosphonic acid anhydride and a solvent comprising dichloromethane to provide the compound of formula 16. 35. A method for preparing a compound of formula 18:
Figure imgf000064_0002
wherein R18 is a suitable protecting group, comprising converting a compound of formula 13:
Figure imgf000065_0001
or a salt thereof, to the compound of formula 18. 36. The method of claim 35, wherein the compound of formula 13 or the salt thereof is converted to the compound of formula 18, by treating the compound of formula 13 with a compound of formula 13CCC:
Figure imgf000065_0002
wherein R18 is a suitable protecting group, or a salt thereof, under suitable coupling conditions. 37. The method of claim 35, wherein a trifluoroacetic acid salt of a compound of formula 13:
Figure imgf000065_0003
is treated with a compound of formula 13CCC, wherein R18 is 4,4-dimethoxytriphenylmethyl under suitable coupling conditions to provide a compound of formula 18:
Figure imgf000066_0001
wherein R18 is 4,4-dimethoxytriphenylmethyl. 38. The method of any one of claims 35-37, wherein the compound of formula 13 is treated with the compound of formula 13CCC in the presence of propanephosphonic acid anhydride and a solvent comprising dichloromethane to provide the compound of formula 18. 39. A method for preparing a compound of formula 16-2:
Figure imgf000066_0002
comprising converting a compound of formula 16-1:
Figure imgf000066_0003
or a salt thereof, to the compound of formula 16-2.
40. A method for preparing a compound of formula 16-3:
Figure imgf000067_0001
comprising converting a compound of formula 16-2:
Figure imgf000067_0002
to the compound of formula 16-3. 41. A method for preparing a compound of formula 16-4:
Figure imgf000067_0003
comprising converting a compound of formula 16-3:
Figure imgf000067_0004
to the compound of formula 16-4.
42. A method for preparing a compound of formula 16-5:
Figure imgf000068_0001
or a salt thereof, comprising converting a compound of formula 16-4:
Figure imgf000068_0002
to the compound of formula 16-5. 43. A method for preparing a compound of formula 16D:
Figure imgf000068_0003
or a salt thereof, comprising converting a compound of formula 16-5:
Figure imgf000069_0001
to the compound of formula 16D. 44. A method for preparing a compound of formula 16E:
Figure imgf000069_0002
or a salt thereof, comprising converting a compound of formula 16D:
Figure imgf000069_0003
or a salt thereof, to the compound of formula 16D.
45. A method for preparing a compound of formula 16:
Figure imgf000070_0001
or a salt thereof, comprising converting a compound of formula 16E:
Figure imgf000070_0002
or a salt thereof, to the compound of formula 16. 46. The method of claim 45, wherein the compound of formula 16E or the salt thereof is converted to the compound of formula 16 or the salt thereof, by reacting the compound of formula 16E or the salt thereof with a compound of formula 11:
Figure imgf000071_0001
or a salt thereof, under suitable coupling conditions.
Figure imgf000071_0002
Kk
Figure imgf000072_0001
or a salt thereof, wherein each R15 is (C1-C6)alkyl and each T is an optionally substituted triphenylmethyl group.
Figure imgf000073_0001
Figure imgf000074_0001
or a salt thereof, wherein each R15 is (C1-C6)alkyl. 49. The salt:
Figure imgf000074_0002
. 50. The method of any one of claims 35-38, further comprising converting the compound of formula 18 to a compound of formula 19:
Figure imgf000074_0003
wherein R19 is a group that comprises an siRNA that is suitable for treating HBV and/or HDV.
51. The method of claim 50, wherein the compound of formula 19 is a compound of formula 20:
Figure imgf000075_0001
wherein the siRNA is suitable for treating HBV and/or HDV. 52. A method for treating HBV and/or HDV infection in a human subject comprising administering to the human subject, a therapeutically effective amount of compound of formula 19 or formula 20 that is prepared as described in claim 50 or 51, and a second therapeutic agent that is useful for treating HBV and/or HDV. 53. The method of claim 52 wherein the second therapeutic agent is an HBV capsid formation inhibitor or an HBV RNA destabilizer. 54. The method of claim 53 wherein the HBV RNA destabilizer is an HBV surface antigen inhibitor. 55. The method of any one of claims 52-54 wherein the compound of formula 19 or formula 20 and the second therapeutic agent are administered separately.
PCT/US2020/065666 2019-12-20 2020-12-17 Synthetic processes and intermediates WO2021127214A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
EP20903872.8A EP4077473A4 (en) 2019-12-20 2020-12-17 Synthetic processes and intermediates
CA3165101A CA3165101A1 (en) 2019-12-20 2020-12-17 Synthetic processes and intermediates
IL294064A IL294064A (en) 2019-12-20 2020-12-17 Synthetic processes and intermediates
JP2022537683A JP2023510109A (en) 2019-12-20 2020-12-17 Synthetic process and intermediates
AU2020408039A AU2020408039A1 (en) 2019-12-20 2020-12-17 Synthetic processes and intermediates
US17/787,089 US20230113948A1 (en) 2019-12-20 2020-12-17 Synthetic processes and intermediates
BR112022012226A BR112022012226A2 (en) 2019-12-20 2020-12-17 METHODS, METHOD FOR PREPARING A CRYSTALLINE FORM, CRYSTALLINE FORM, COMPOUNDS AND SALT
KR1020227022805A KR20220119052A (en) 2019-12-20 2020-12-17 Synthetic processes and intermediates
CN202080089979.8A CN114846051A (en) 2019-12-20 2020-12-17 Synthetic methods and intermediates
MX2022007738A MX2022007738A (en) 2019-12-20 2020-12-17 Synthetic processes and intermediates.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962951836P 2019-12-20 2019-12-20
US62/951,836 2019-12-20

Publications (2)

Publication Number Publication Date
WO2021127214A1 true WO2021127214A1 (en) 2021-06-24
WO2021127214A4 WO2021127214A4 (en) 2021-08-12

Family

ID=76478539

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/065666 WO2021127214A1 (en) 2019-12-20 2020-12-17 Synthetic processes and intermediates

Country Status (12)

Country Link
US (1) US20230113948A1 (en)
EP (1) EP4077473A4 (en)
JP (1) JP2023510109A (en)
KR (1) KR20220119052A (en)
CN (1) CN114846051A (en)
AU (1) AU2020408039A1 (en)
BR (1) BR112022012226A2 (en)
CA (1) CA3165101A1 (en)
IL (1) IL294064A (en)
MX (1) MX2022007738A (en)
TW (1) TW202136227A (en)
WO (1) WO2021127214A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023143374A1 (en) * 2022-01-30 2023-08-03 成都凌泰氪生物技术有限公司 Ligand, method for preparing same, and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080194549A1 (en) * 2005-03-23 2008-08-14 Claus Ehrhardt Organic Compounds
WO2013058824A1 (en) * 2011-04-07 2013-04-25 Cornell University Monomers capable of dimerizing in an aqueous solution, and methods of using same
US20190160176A1 (en) * 2016-04-11 2019-05-30 Arbutus Biopharma Corporation Targeted nucleic acid conjugate compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3950004A1 (en) * 2017-04-11 2022-02-09 Arbutus Biopharma Corporation Targeted compositions
MX2021005130A (en) * 2018-11-02 2021-11-04 Genevant Sciences Gmbh Therapeutic methods.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080194549A1 (en) * 2005-03-23 2008-08-14 Claus Ehrhardt Organic Compounds
WO2013058824A1 (en) * 2011-04-07 2013-04-25 Cornell University Monomers capable of dimerizing in an aqueous solution, and methods of using same
US20190160176A1 (en) * 2016-04-11 2019-05-30 Arbutus Biopharma Corporation Targeted nucleic acid conjugate compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP4077473A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023143374A1 (en) * 2022-01-30 2023-08-03 成都凌泰氪生物技术有限公司 Ligand, method for preparing same, and use thereof

Also Published As

Publication number Publication date
JP2023510109A (en) 2023-03-13
KR20220119052A (en) 2022-08-26
CN114846051A (en) 2022-08-02
MX2022007738A (en) 2022-07-19
BR112022012226A2 (en) 2022-09-13
EP4077473A1 (en) 2022-10-26
CA3165101A1 (en) 2021-06-24
AU2020408039A1 (en) 2022-08-18
WO2021127214A4 (en) 2021-08-12
TW202136227A (en) 2021-10-01
EP4077473A4 (en) 2024-05-01
US20230113948A1 (en) 2023-04-13
IL294064A (en) 2022-08-01

Similar Documents

Publication Publication Date Title
EP0303697B1 (en) Derivatives of physiologically active substance k-252
KR101476626B1 (en) Cyclosporin analogues for preventing or treating hepatitis c infection
WO2018226801A1 (en) Aryldiazepine derivatives as rsv inhibitors
KR20190056436A (en) Isoxazole analogs as FXR agonists and methods for their use
KR20080006004A (en) 2-amido-6-amino-8-oxopurine derivatives as toll-like receptor modulators for the treatment of cancer and viral infections, such as hepatitis c
EP2399904A1 (en) Process for the preparation of pleuromutilins
TW202321251A (en) Novel spiropyrrolidine derived antiviral agents
CA2684557A1 (en) New cyclic peptide compounds
CA2082216A1 (en) Polycyclic conjugates
EP1870411B1 (en) Process for the preparation and purification of valgancyclovir
AU2012361285A1 (en) Sialic acid dimers
AU4061193A (en) Novel adenosine derivatives
CA2180006A1 (en) Diastereomeric pure trifluoromethyl ketone peptide derivatives as inhibitors of human leukocyte elastase
EP4077473A1 (en) Synthetic processes and intermediates
WO1997000262A1 (en) Phosphonate nucleotide derivatives
JP2019515014A (en) Secoma chloride compound
JP2007291050A (en) Synthesis and use of pyroglutamic acid derivative
CA2658917C (en) 3&#39;-ethynylcytidine derivative
CN111747949B (en) Bcl-2 selective inhibitors
WO2022010882A1 (en) Dihydroquinoxaline and dihydropyridopyrazine derivatives as rsv inhibitors
KR100971347B1 (en) Ns3 protease inhibitors for the treatment of hepatitis c virus infection
CN118084881A (en) PROTAC small molecules, pharmaceutical composition and application thereof
NO178729B (en) Therapeutically active sugar derivatives
CA3235452A1 (en) Novel crystalline forms
EP4099991A1 (en) Novel processes for preparation of tezacaftor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20903872

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3165101

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2022537683

Country of ref document: JP

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112022012226

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20227022805

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020903872

Country of ref document: EP

Effective date: 20220720

ENP Entry into the national phase

Ref document number: 2020408039

Country of ref document: AU

Date of ref document: 20201217

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112022012226

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20220620